Metabolite

KNApSAcK Entry

id C00000958
Name (-)-Epigallocatechin gallate / epi-Gallocatechin 3-O-gallate / (2R-cis)-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester 3,4,5-trihydroxybenzoic acid
CAS RN 989-51-5
Standard InChI InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1
Standard InChI (Main Layer) InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2

Cluster

Phytochemical cluster No. 14
KCF-S cluster No. 219

Link

ChEMBL

By standard InChI CHEMBL297453
By standard InChI Main Layer CHEMBL297453 CHEMBL311663 CHEMBL126079 CHEMBL338988 CHEMBL264938

KEGG

By LinkDB C09731

CTD

By CAS RN C045651

Human Protein / Gene in interaction

49 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
Q9UIF8 Bromodomain adjacent to zinc finger domain protein 2B Unclassified protein CHEMBL297453 CHEMBL1738312 (1)
0 / 0
O95342 Bile salt export pump drug CHEMBL297453 CHEMBL2076226 (1) CHEMBL2076242 (1)
2 / 1
P14618 Pyruvate kinase PKM Enzyme CHEMBL297453 CHEMBL1613996 (1) CHEMBL1614428 (1)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL297453 CHEMBL1008507 (1)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL311663 CHEMBL1676103 (1)
2 / 2
P08246 Neutrophil elastase S1A CHEMBL297453 CHEMBL1071298 (1) CHEMBL1071299 (1)
CHEMBL1071300 (1) CHEMBL1071301 (1)
CHEMBL1071302 (1) CHEMBL1071303 (1)
2 / 1
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL297453 CHEMBL1664298 (1)
0 / 0
P06746 DNA polymerase beta Enzyme CHEMBL297453 CHEMBL1614079 (1)
0 / 0
P10253 Lysosomal alpha-glucosidase Hydrolase CHEMBL297453 CHEMBL1614076 (1)
1 / 1
P52209 6-phosphogluconate dehydrogenase, decarboxylating Enzyme CHEMBL297453 CHEMBL264938 CHEMBL921930 (2)
0 / 0
O75604 Ubiquitin carboxyl-terminal hydrolase 2 Enzyme CHEMBL311663 CHEMBL1614331 (1)
0 / 0
P10828 Thyroid hormone receptor beta NR1A2 CHEMBL297453 CHEMBL1794399 (1)
3 / 1
P02768 Serum albumin Secreted protein CHEMBL297453 CHEMBL1177441 (1) CHEMBL2340743 (1)
CHEMBL2340744 (1)
0 / 0
P49327 Fatty acid synthase Transferase CHEMBL297453 CHEMBL1260142 (1)
0 / 0
P54132 Bloom syndrome protein Enzyme CHEMBL311663 CHEMBL1614067 (1)
1 / 2
P51570 Galactokinase Enzyme CHEMBL311663 CHEMBL1613821 (1)
1 / 1
P11473 Vitamin D3 receptor NR1I1 CHEMBL311663 CHEMBL1794311 (1)
2 / 3
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL297453 CHEMBL1008508 (1)
0 / 0
P00352 Retinal dehydrogenase 1 Enzyme CHEMBL311663 CHEMBL1614458 (1)
0 / 0
P50281 Matrix metalloproteinase-14 M10A CHEMBL297453 CHEMBL1064084 (1)
0 / 0
Q92830 Histone acetyltransferase KAT2A Enzyme CHEMBL311663 CHEMBL1738606 (1)
0 / 0
O94782 Ubiquitin carboxyl-terminal hydrolase 1 Enzyme CHEMBL311663 CHEMBL1794467 (1)
0 / 0
P37231 Peroxisome proliferator-activated receptor gamma NR1C3 CHEMBL297453 CHEMBL1794510 (1)
5 / 3
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL297453 CHEMBL2090538 (1)
5 / 10
P08581 Hepatocyte growth factor receptor TK tyrosine-protein kinase MET subfamily CHEMBL297453 CHEMBL264938 CHEMBL1056838 (2) CHEMBL1056839 (2)
CHEMBL1056840 (1)
2 / 3
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL311663 CHEMBL1613808 (1)
0 / 0
P56817 Beta-secretase 1 A1A CHEMBL297453 CHEMBL126079 CHEMBL338988 CHEMBL653507 (2) CHEMBL653508 (2)
CHEMBL1954848 (1) CHEMBL1954849 (1)
CHEMBL1954850 (1) CHEMBL1954851 (1)
CHEMBL1954852 (1) CHEMBL1954997 (1)
CHEMBL1955004 (1) CHEMBL1955005 (1)
CHEMBL1955006 (1) CHEMBL1955007 (1)
CHEMBL1955014 (1) CHEMBL1955015 (1)
CHEMBL1955016 (1) CHEMBL1955017 (1)
CHEMBL1955020 (1) CHEMBL1955021 (1)
CHEMBL1955023 (1) CHEMBL1955024 (1)
CHEMBL1953025 (1) CHEMBL1953026 (1)
CHEMBL1953027 (1) CHEMBL1953030 (1)
CHEMBL1953031 (1)
0 / 0
P09237 Matrilysin M10A CHEMBL297453 CHEMBL1064085 (1)
0 / 0
P08253 72 kDa type IV collagenase M10A CHEMBL297453 CHEMBL1064086 (1)
1 / 3
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 Enzyme CHEMBL311663 CHEMBL1613910 (1)
3 / 3
P15428 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Enzyme CHEMBL311663 CHEMBL1614038 (1)
2 / 2
P00374 Dihydrofolate reductase Oxidoreductase CHEMBL297453 CHEMBL930269 (1)
1 / 1
P26358 DNA (cytosine-5)-methyltransferase 1 Transferase CHEMBL297453 CHEMBL2066853 (1)
2 / 0
P19838 Nuclear factor NF-kappa-B p105 subunit Transcription Factor CHEMBL297453 CHEMBL2114853 (1)
0 / 0
P16050 Arachidonate 15-lipoxygenase Enzyme CHEMBL311663 CHEMBL1614240 (1)
0 / 0
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL311663 CHEMBL1614108 (1) CHEMBL1613886 (1)
0 / 1
P27695 DNA-(apurinic or apyrimidinic site) lyase Enzyme CHEMBL297453 CHEMBL311663 CHEMBL1614466 (1) CHEMBL1614211 (2)
0 / 0
P10636 Microtubule-associated protein tau Unclassified protein CHEMBL297453 CHEMBL311663 CHEMBL1614250 (2) CHEMBL1614421 (2)
CHEMBL1614502 (2)
4 / 3
Q16236 Nuclear factor erythroid 2-related factor 2 Unclassified protein CHEMBL297453 CHEMBL2114890 (1)
0 / 0
Q13627 Dual specificity tyrosine-phosphorylation-regulated kinase 1A CMGC dual-specificity kinase DYRK1 CHEMBL297453 CHEMBL1937068 (1) CHEMBL1937069 (1)
CHEMBL1937071 (1) CHEMBL1937072 (1)
1 / 0
O14746 Telomerase reverse transcriptase Enzyme CHEMBL297453 CHEMBL2175294 (1) CHEMBL2175297 (1)
CHEMBL2175302 (1) CHEMBL2175304 (1)
CHEMBL2175309 (1) CHEMBL2175310 (1)
5 / 5
P10415 Apoptosis regulator Bcl-2 Other cytosolic protein CHEMBL297453 CHEMBL937576 (1)
0 / 7
Q9UBT6 DNA polymerase kappa Enzyme CHEMBL311663 CHEMBL1794536 (1)
0 / 0
B2RXH2 Lysine-specific demethylase 4E Enzyme CHEMBL297453 CHEMBL311663 CHEMBL1613914 (2)
0 / 0
P46063 ATP-dependent DNA helicase Q1 Enzyme CHEMBL297453 CHEMBL311663 CHEMBL1613829 (2)
0 / 0
Q96KQ7 Histone-lysine N-methyltransferase EHMT2 Enzyme CHEMBL297453 CHEMBL1738442 (1)
0 / 0
Q9NUW8 Tyrosyl-DNA phosphodiesterase 1 Enzyme CHEMBL297453 CHEMBL311663 CHEMBL1614364 (2)
1 / 1
O00255 Menin Unclassified protein CHEMBL297453 CHEMBL311663 CHEMBL1614257 (2)
2 / 5
Q03164 Histone-lysine N-methyltransferase 2A Enzyme CHEMBL297453 CHEMBL311663 CHEMBL1614257 (2)
1 / 3

CTD interaction (2358)

compound gene gene name gene description interaction interaction type form reference
pmid
C045651 195827 AAED1
C9orf21
AhpC/TSA antioxidant enzyme domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AAED1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 28971 AAMDC
C11orf67
CK067
adipogenesis associated, Mth938 domain containing [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AAMDC mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25980 AAR2
C20orf4
AAR2 splicing factor homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AAR2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 132949 AASDH
ACSF4
LYS2
NRPS1098
NRPS998
aminoadipate-semialdehyde dehydrogenase (EC:6.2.1.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AASDH mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) epigallocatechin gallate results in decreased expression of ABCB1 mRNA decreases expression
mRNA 18851785
C045651 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) epigallocatechin gallate results in decreased expression of ABCB1 protein decreases expression
protein 20149610
C045651 23456 ABCB10
EST20237
M-ABC2
MTABC2
ATP-binding cassette, sub-family B (MDR/TAP), member 10 epigallocatechin gallate results in increased expression of ABCB10 mRNA increases expression
mRNA 18851785
C045651 8647 ABCB11
ABC16
BRIC2
BSEP
PFIC-2
PFIC2
PGY4
SPGP
ATP-binding cassette, sub-family B (MDR/TAP), member 11 epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA] decreases reaction
/ increases expression
mRNA 22178739
C045651 8647 ABCB11
ABC16
BRIC2
BSEP
PFIC-2
PFIC2
PGY4
SPGP
ATP-binding cassette, sub-family B (MDR/TAP), member 11 epigallocatechin gallate inhibits the reaction [GW 4064 results in increased expression of ABCB11 mRNA] decreases reaction
/ increases expression
mRNA 22178739
C045651 8647 ABCB11
ABC16
BRIC2
BSEP
PFIC-2
PFIC2
PGY4
SPGP
ATP-binding cassette, sub-family B (MDR/TAP), member 11 epigallocatechin gallate results in increased expression of ABCB11 mRNA increases expression
mRNA 22178739
C045651 89845 ABCC10
EST182763
MRP7
SIMRP7
ATP-binding cassette, sub-family C (CFTR/MRP), member 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABCC10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10057 ABCC5
ABC33
EST277145
MOAT-C
MOATC
MRP5
SMRP
pABC11
ATP-binding cassette, sub-family C (CFTR/MRP), member 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABCC5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5825 ABCD3
ABC43
PMP70
PXMP1
ZWS2
ATP-binding cassette, sub-family D (ALD), member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABCD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6059 ABCE1
ABC38
OABP
RLI
RNASEL1
RNASELI
RNS4I
ATP-binding cassette, sub-family E (OABP), member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABCE1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9619 ABCG1
ABC8
WHITE1
ATP-binding cassette, sub-family G (WHITE), member 1 epigallocatechin gallate results in decreased expression of ABCG1 mRNA decreases expression
mRNA 16084531
C045651 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 epigallocatechin gallate results in decreased activity of ABCG2 protein decreases activity
protein 20149610
C045651 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 epigallocatechin gallate results in increased expression of ABCG2 mRNA increases expression
mRNA 18851785
C045651 57406 ABHD6
abhydrolase domain containing 6 (EC:3.1.1.23) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABHD6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27 ABL2
ABLL
ARG
c-abl oncogene 2, non-receptor tyrosine kinase (EC:2.7.10.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ABL2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 29 ABR
MDB
active BCR-related [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 34 ACADM
ACAD1
MCAD
MCADH
acyl-CoA dehydrogenase, C-4 to C-12 straight chain (EC:1.3.8.7) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ACADM mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23527 ACAP2
CENTB2
CNT-B2
ArfGAP with coiled-coil, ankyrin repeat and PH domains 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ACAP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 47 ACLY
ACL
ATPCL
CLATP
ATP citrate lyase (EC:2.3.3.8) epigallocatechin gallate results in increased expression of ACLY mRNA increases expression
mRNA 20706672
C045651 55860 ACTR10
ACTR11
Arp11
HARP11
actin-related protein 10 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ACTR10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8728 ADAM19
MADDAM
MLTNB
ADAM metallopeptidase domain 19 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAM19 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8748 ADAM20
ADAM metallopeptidase domain 20 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ADAM20 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 81792 ADAMTS12
PRO4389
ADAM metallopeptidase with thrombospondin type 1 motif, 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAMTS12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 170689 ADAMTS15
ADAM metallopeptidase with thrombospondin type 1 motif, 15 epigallocatechin gallate results in increased expression of ADAMTS15 mRNA increases expression
mRNA 22079256
C045651 170689 ADAMTS15
ADAM metallopeptidase with thrombospondin type 1 motif, 15 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAMTS15 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11096 ADAMTS5
ADAM-TS_11
ADAM-TS_5
ADAM-TS5
ADAMTS-11
ADAMTS-5
ADAMTS11
ADMP-2
ADAM metallopeptidase with thrombospondin type 1 motif, 5 epigallocatechin gallate results in increased expression of ADAMTS5 mRNA increases expression
mRNA 22079256
C045651 11096 ADAMTS5
ADAM-TS_11
ADAM-TS_5
ADAM-TS5
ADAMTS-11
ADAMTS-5
ADAMTS11
ADMP-2
ADAM metallopeptidase with thrombospondin type 1 motif, 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAMTS5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 574406 ADAMTSL4-AS1
C1orf138
ADAMTSL4 antisense RNA 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ADAMTSL4-AS1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 104 ADARB1
ADAR2
DRABA2
DRADA2
RED1
adenosine deaminase, RNA-specific, B1 (EC:3.5.4.37) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADARB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23536 ADAT1
HADAT1
adenosine deaminase, tRNA-specific 1 (EC:3.5.4.34) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 100380740 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ADFP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 133 ADM
AM
adrenomedullin epigallocatechin gallate results in decreased secretion of ADM protein decreases secretion
protein 22178239
C045651 147 ADRA1B
ADRA1
ALPHA1BAR
adrenoceptor alpha 1B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADRA1B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 154 ADRB2
ADRB2R
ADRBR
B2AR
BAR
BETA2AR
adrenoceptor beta 2, surface [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ADRB2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 157 ADRBK2
BARK2
GRK3
adrenergic, beta, receptor kinase 2 (EC:2.7.11.15) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADRBK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 159 ADSS
ADEH
ADSS_2
adenylosuccinate synthase (EC:6.3.4.4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADSS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4299 AFF1
AF4
MLLT2
PBM1
AF4/FMR2 family, member 1 epigallocatechin gallate results in increased expression of AFF1 mRNA increases expression
mRNA 22079256
C045651 4299 AFF1
AF4
MLLT2
PBM1
AF4/FMR2 family, member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AFF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 116987 AGAP1
AGAP-1
CENTG2
GGAP1
cnt-g2
ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AGAP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 178 AGL
GDE
amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase (EC:2.4.1.25 3.2.1.33) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AGL mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8540 AGPS
ADAP-S
ADAS
ADHAPS
ADPS
ALDHPSY
alkylglycerone phosphate synthase (EC:2.5.1.26) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AGPS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 185 AGTR1
AG2S
AGTR1A
AGTR1B
AT1
AT1AR
AT1B
AT1BR
AT1R
AT2R1
AT2R1A
AT2R1B
HAT1R
angiotensin II receptor, type 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AGTR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 191 AHCY
SAHH
adoHcyase
adenosylhomocysteinase (EC:3.3.1.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AHCY mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 196 AHR
bHLHe76
aryl hydrocarbon receptor epigallocatechin gallate binds to and results in decreased activity of AHR protein affects binding
/ decreases activity
protein 11064004
C045651 196 AHR
bHLHe76
aryl hydrocarbon receptor epigallocatechin gallate inhibits the reaction [[Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA] affects binding
/ decreases reaction
/ increases activity
/ increases expression
protein 11064004
C045651 196 AHR
bHLHe76
aryl hydrocarbon receptor epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased localization of AHR protein] decreases reaction
/ increases localization
protein 20450880
C045651 196 AHR
bHLHe76
aryl hydrocarbon receptor epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of AHR protein] decreases reaction
/ increases phosphorylation
protein 20450880
C045651 64853 AIDA
C1orf80
RP11-378J18.7
axin interactor, dorsalization associated [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AIDA mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9131 AIFM1
AIF
CMTX4
COWCK
COXPD6
PDCD8
apoptosis-inducing factor, mitochondrion-associated, 1 epigallocatechin gallate analog affects the localization of AIFM1 protein affects localization
protein 16115949
C045651 9255 AIMP1
EMAP2
EMAPII
HLD3
SCYE1
p43
aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 epigallocatechin gallate results in decreased expression of AIMP1 mRNA decreases expression
mRNA 16084531
C045651 84962 AJUBA
JUB
ajuba LIM protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AJUBA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11214 AKAP13
AKAP-13
AKAP-Lbc
ARHGEF13
BRX
HA-3
Ht31
LBC
PRKA13
PROTO-LB
PROTO-LBC
c-lbc
p47
A kinase (PRKA) anchor protein 13 epigallocatechin gallate results in increased expression of AKAP13 mRNA increases expression
mRNA 22079256
C045651 11214 AKAP13
AKAP-13
AKAP-Lbc
ARHGEF13
BRX
HA-3
Ht31
LBC
PRKA13
PROTO-LB
PROTO-LBC
c-lbc
p47
A kinase (PRKA) anchor protein 13 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKAP13 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56672 AKIP1
BCA3
C11orf17
A kinase (PRKA) interacting protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKIP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55122 AKIRIN2
C6orf166
FBI1
dJ486L4.2
akirin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AKIRIN2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8644 AKR1C3
DD3
DDX
HA1753
HAKRB
HAKRe
HSD17B5
PGFS
hluPGFS
aldo-keto reductase family 1, member C3 (EC:1.3.1.20 1.1.1.188 1.1.1.239 1.1.1.64 1.1.1.112 1.1.1.357) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKR1C3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of AKT1 protein] decreases reaction
/ increases phosphorylation
protein 19244381
C045651 10000 AKT3
MPPH
PKB-GAMMA
PKBG
PRKBG
RAC-PK-gamma
RAC-gamma
STK-2
v-akt murine thymoma viral oncogene homolog 3 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKT3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64400 AKTIP
FT1
FTS
AKT interacting protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKTIP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 224 ALDH3A2
ALDH10
FALDH
SLS
aldehyde dehydrogenase 3 family, member A2 (EC:1.2.1.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALDH3A2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 199857 ALG14
ALG14, UDP-N-acetylglucosaminyltransferase subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALG14 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29929 ALG6
CDG1C
ALG6, alpha-1,3-glucosyltransferase (EC:2.4.1.267) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALG6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79053 ALG8
CDG1H
ALG8, alpha-1,3-glucosyltransferase (EC:2.4.1.265) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALG8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 115701 ALPK2
HAK
alpha-kinase 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALPK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 268 AMH
MIF
MIS
anti-Mullerian hormone [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AMH mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9949 AMMECR1
AMMERC1
Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AMMECR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 270 AMPD1
MAD
MADA
MMDD
adenosine monophosphate deaminase 1 (EC:3.5.4.6) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AMPD1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10393 ANAPC10
APC10
DOC1
anaphase promoting complex subunit 10 epigallocatechin gallate results in decreased expression of ANAPC10 mRNA decreases expression
mRNA 22079256
C045651 10393 ANAPC10
APC10
DOC1
anaphase promoting complex subunit 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANAPC10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29945 ANAPC4
APC4
anaphase promoting complex subunit 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANAPC4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51434 ANAPC7
APC7
anaphase promoting complex subunit 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANAPC7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54467 ANKIB1
ankyrin repeat and IBR domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKIB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57037 ANKMY2
ZMYND20
ankyrin repeat and MYND domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKMY2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55608 ANKRD10
ankyrin repeat domain 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ANKRD10 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 22852 ANKRD26
THC2
bA145E8.1
ankyrin repeat domain 26 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKRD26 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 375248 ANKRD36
UNQ2430
ankyrin repeat domain 36 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKRD36 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 91526 ANKRD44
PP6-ARS-B
ankyrin repeat domain 44 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKRD44 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 121601 ANO4
TMEM16D
anoctamin 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANO4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 130340 AP1S3
adaptor-related protein complex 1, sigma 3 subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AP1S3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 161 AP2A2
ADTAB
CLAPA2
HIP-9
HIP9
HYPJ
adaptor-related protein complex 2, alpha 2 subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AP2A2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55317 AP5S1
C20orf29
adaptor-related protein complex 5, sigma 1 subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AP5S1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 317 APAF1
APAF-1
CED4
apoptotic peptidase activating factor 1 epigallocatechin gallate results in increased expression of APAF1 protein increases expression
protein 15657356
C045651 323 APBB2
FE65L
FE65L1
amyloid beta (A4) precursor protein-binding, family B, member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of APBB2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83464 APH1B
APH-1B
PRO1328
PSFL
TAAV688
APH1B gamma secretase subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of APH1B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23780 APOL2
APOL-II
APOL3
apolipoprotein L, 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of APOL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55198 APPL2
DIP13B
adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of APPL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 358 AQP1
AQP-CHIP
CHIP28
CO
aquaporin 1 epigallocatechin gallate results in decreased expression of AQP1 mRNA decreases expression
mRNA 20706672
C045651 358 AQP1
AQP-CHIP
CHIP28
CO
aquaporin 1 epigallocatechin gallate results in increased expression of AQP1 mRNA increases expression
mRNA 20706672
C045651 360 AQP3
AQP-3
GIL
aquaporin 3 (Gill blood group) epigallocatechin gallate results in increased expression of AQP3 mRNA increases expression
mRNA 20706672
C045651 9716 AQR
IBP160
fSAP164
aquarius intron-binding spliceosomal factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AQR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 367 AR
AIS
DHTR
HUMARA
HYSP1
KD
NR3C4
SBMA
SMAX1
TFM
androgen receptor epigallocatechin gallate results in decreased expression of AR mRNA decreases expression
mRNA 20706672
C045651 64411 ARAP3
CENTD3
DRAG1
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARAP3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10565 ARFGEF1
ARFGEP1
BIG1
P200
ADP-ribosylation factor guanine nucleotide-exchange factor 1 (brefeldin A-inhibited) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARFGEF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79658 ARHGAP10
GRAF2
PS-GAP
PSGAP
Rho GTPase activating protein 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9824 ARHGAP11A
GAP_(1-12)
Rho GTPase activating protein 11A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP11A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 94134 ARHGAP12
Rho GTPase activating protein 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 93663 ARHGAP18
MacGAP
SENEX
bA307O14.2
Rho GTPase activating protein 18 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP18 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57569 ARHGAP20
RARHOGAP
Rho GTPase activating protein 20 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP20 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57584 ARHGAP21
ARHGAP10
Rho GTPase activating protein 21 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP21 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83478 ARHGAP24
FILGAP
RC-GAP72
RCGAP72
p73
p73RhoGAP
Rho GTPase activating protein 24 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP24 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79822 ARHGAP28
Rho GTPase activating protein 28 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP28 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9411 ARHGAP29
PARG1
RP11-255E17.1
Rho GTPase activating protein 29 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP29 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26084 ARHGEF26
CSGEF
HMFN1864
SGEF
Rho guanine nucleotide exchange factor (GEF) 26 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGEF26 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64283 ARHGEF28
RGNEF
RIP2
p190RHOGEF
Rho guanine nucleotide exchange factor (GEF) 28 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGEF28 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 50650 ARHGEF3
GEF3
STA3
XPLN
Rho guanine nucleotide exchange factor (GEF) 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGEF3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54622 ARL15
ARFRP2
ADP-ribosylation factor-like 15 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARL15 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55156 ARMC1
Arcp
armadillo repeat containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARMC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55130 ARMC4
CILD23
armadillo repeat containing 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARMC4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80210 ARMC9
ARM
KU-MEL-1
armadillo repeat containing 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARMC9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 405 ARNT
HIF-1-beta
HIF-1beta
HIF1-beta
HIF1B
HIF1BETA
TANGO
bHLHe2
aryl hydrocarbon receptor nuclear translocator epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of ARNT protein] decreases reaction
/ increases phosphorylation
protein 20450880
C045651 405 ARNT
HIF-1-beta
HIF-1beta
HIF1-beta
HIF1B
HIF1BETA
TANGO
bHLHe2
aryl hydrocarbon receptor nuclear translocator [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARNT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 406 ARNTL
BMAL1
BMAL1c
JAP3
MOP3
PASD3
TIC
bHLHe5
aryl hydrocarbon receptor nuclear translocator-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARNTL mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 81873 ARPC5L
ARC16-2
actin related protein 2/3 complex, subunit 5-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ARPC5L mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 408 ARRB1
ARB1
ARR1
arrestin, beta 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARRB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57561 ARRDC3
TLIMP
arrestin domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ARRDC3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 340075 ARSI
arylsulfatase family, member I [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARSI mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79642 ARSJ
arylsulfatase family, member J (EC:3.1.6.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARSJ mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 420 ART4
ARTC4
CD297
DO
DOK1
ADP-ribosyltransferase 4 (EC:2.4.2.31) epigallocatechin gallate results in decreased expression of ART4 mRNA decreases expression
mRNA 16084531
C045651 64801 ARV1
ARV1 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARV1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 50807 ASAP1
AMAP1
CENTB4
DDEF1
PAG2
PAP
ZG14P
ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASAP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 140459 ASB6
ankyrin repeat and SOCS box containing 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ASB6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10973 ASCC3
ASC1p200
HELIC1
RNAH
activating signal cointegrator 1 complex subunit 3 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASCC3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25842 ASF1A
CGI-98
CIA
HSPC146
anti-silencing function 1A histone chaperone [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASF1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9070 ASH2L
ASH2
ASH2L1
ASH2L2
Bre2
ash2 (absent, small, or homeotic)-like (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASH2L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 259266 ASPM
ASP
Calmbp1
MCPH5
asp (abnormal spindle) homolog, microcephaly associated (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASPM mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54454 ATAD2B
ATPase family, AAA domain containing 2B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATAD2B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11101 ATE1
arginyltransferase 1 (EC:2.3.2.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATE1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 467 ATF3
activating transcription factor 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATF3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 468 ATF4
CREB-2
CREB2
TAXREB67
TXREB
activating transcription factor 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATF4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 83734 ATG10
APG10
APG10L
pp12616
autophagy related 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATG10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 115201 ATG4A
APG4A
AUTL2
autophagy related 4A, cysteine peptidase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATG4A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84938 ATG4C
APG4-C
APG4C
AUTL1
AUTL3
autophagy related 4C, cysteine peptidase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATG4C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84971 ATG4D
APG4-D
APG4D
AUTL4
autophagy related 4D, cysteine peptidase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATG4D mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9474 ATG5
APG5
APG5-LIKE
APG5L
ASP
hAPG5
autophagy related 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATG5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51062 ATL1
AD-FSP
FSP1
GBP3
HSN1D
SPG3
SPG3A
atlastin1
atlastin GTPase 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1822 ATN1
B37
D12S755E
DRPLA
HRS
NOD
atrophin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATN1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 57205 ATP10D
ATPVD
ATPase, class V, type 10D (EC:3.6.3.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP10D mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 481 ATP1B1
ATP1B
ATPase, Na+/K+ transporting, beta 1 polypeptide [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP1B1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 488 ATP2A2
ATP2B
DAR
DD
SERCA2
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 (EC:3.6.3.8) epigallocatechin gallate results in increased expression of ATP2A2 mRNA increases expression
mRNA 16084531
C045651 490 ATP2B1
PMCA1
PMCA1kb
ATPase, Ca++ transporting, plasma membrane 1 (EC:3.6.3.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP2B1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 493 ATP2B4
ATP2B2
MXRA1
PMCA4
PMCA4b
PMCA4x
ATPase, Ca++ transporting, plasma membrane 4 (EC:3.6.3.8) epigallocatechin gallate results in increased expression of ATP2B4 mRNA increases expression
mRNA 22079256
C045651 493 ATP2B4
ATP2B2
MXRA1
PMCA4
PMCA4b
PMCA4x
ATPase, Ca++ transporting, plasma membrane 4 (EC:3.6.3.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP2B4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 267020 ATP5L2
ATP5K2
ATP synthase, H+ transporting, mitochondrial Fo complex, subunit G2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATP5L2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 527 ATP6V0C
ATP6C
ATP6L
ATPL
VATL
VPPC
Vma3
ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c (EC:3.6.3.14) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATP6V0C mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 540 ATP7B
PWD
WC1
WD
WND
ATPase, Cu++ transporting, beta polypeptide (EC:3.6.3.54) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP7B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5205 ATP8B1
ATPIC
BRIC
FIC1
ICP1
PFIC
PFIC1
ATPase, aminophospholipid transporter, class I, type 8B, member 1 (EC:3.6.3.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP8B1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 545 ATR
FCTCS
FRP1
MEC1
SCKL
SCKL1
ataxia telangiectasia and Rad3 related (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6311 ATXN2
ASL13
ATX2
SCA2
TNRC13
ataxin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATXN2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11273 ATXN2L
A2D
A2LG
A2LP
A2RP
ataxin 2-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATXN2L mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4287 ATXN3
AT3
ATX3
JOS
MJD
MJD1
SCA3
ataxin 3 (EC:3.4.19.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATXN3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 222255 ATXN7L1
ATXN7L4
ataxin 7-like 1 epigallocatechin gallate results in increased expression of ATXN7L1 mRNA increases expression
mRNA 22079256
C045651 222255 ATXN7L1
ATXN7L4
ataxin 7-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATXN7L1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6790 AURKA
AIK
ARK1
AURA
AURORA2
BTAK
PPP1R47
STK15
STK6
STK7
aurora kinase A (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AURKA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 33419 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AXUD1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51582 AZIN1
OAZI
OAZIN
ODC1L
antizyme inhibitor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AZIN1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 145173 B3GALTL
B3GLCT
B3GTL
B3Glc-T
Gal-T
beta3Glc-T
beta 1,3-galactosyltransferase-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of B3GALTL mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 146712 B3GNTL1
B3GNT8
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like 1 (EC:2.4.1.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of B3GNTL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 570 BAAT
BACAT
BAT
bile acid CoA: amino acid N-acyltransferase (glycine N-choloyltransferase) (EC:2.3.1.65 3.1.2.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAAT mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23621 BACE1
ASP2
BACE
HSPC104
beta-site APP-cleaving enzyme 1 (EC:3.4.23.46) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BACE1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 573 BAG1
BAG-1
HAP
RAP46
BCL2-associated athanogene [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAG1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9532 BAG2
BAG-2
dJ417I1.2
BCL2-associated athanogene 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BAG2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9531 BAG3
BAG-3
BIS
CAIR-1
MFM6
BCL2-associated athanogene 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAG3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9530 BAG4
BAG-4
SODD
BCL2-associated athanogene 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAG4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7917 BAG6
BAG-6
BAT3
D6S52E
G3
BCL2-associated athanogene 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAG6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 578 BAK1
BAK
BAK-LIKE
BCL2L7
CDN1
BCL2-antagonist/killer 1 epigallocatechin gallate results in decreased expression of BAK1 mRNA decreases expression
mRNA 18851785
C045651 581 BAX
BCL2L4
BCL2-associated X protein BAX protein results in increased susceptibility to epigallocatechin gallate increases response to substance
protein 15764647
C045651 581 BAX
BCL2L4
BCL2-associated X protein [decitabine co-treated with epigallocatechin gallate] affects the expression of BAX mRNA affects cotreatment
/ affects expression
mRNA 18250043
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate affects the expression of BAX protein affects expression
protein 15975156
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate analog affects the localization of BAX protein affects localization
protein 16115949
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein] decreases reaction
/ increases expression
protein 12672908
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate promotes the reaction [BAX protein binds to BAX protein] affects binding
/ increases reaction
protein 15705601
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate results in decreased expression of BAX mRNA decreases expression
mRNA 18851785
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate results in increased activity of BAX protein increases activity
protein 15705601
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate results in increased expression of BAX protein increases expression
protein 15657356
15764647
20149610
C045651 11177 BAZ1A
ACF1
WALp1
WCRF180
hACF1
bromodomain adjacent to zinc finger domain, 1A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BAZ1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29994 BAZ2B
WALp4
bromodomain adjacent to zinc finger domain, 2B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BAZ2B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79738 BBS10
C12orf58
Bardet-Biedl syndrome 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BBS10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 583 BBS2
BBS
Bardet-Biedl syndrome 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BBS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 585 BBS4
Bardet-Biedl syndrome 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BBS4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56987 BBX
ARTC1
HBP2
HSPC339
MDS001
bobby sox homolog (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BBX mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [arsenic trioxide co-treated with epigallocatechin gallate] results in decreased expression of BCL2 protein affects cotreatment
/ decreases expression
protein 20950636
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 CAT protein inhibits the reaction [epigallocatechin gallate analog results in decreased expression of BCL2 protein] decreases expression
/ decreases reaction
protein 16115949
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [decitabine co-treated with epigallocatechin gallate] affects the expression of BCL2 mRNA affects cotreatment
/ affects expression
mRNA 18250043
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 epigallocatechin gallate affects the expression of BCL2 protein affects expression
protein 15975156
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 epigallocatechin gallate analog results in decreased expression of BCL2 protein decreases expression
protein 16115949
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 epigallocatechin gallate inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein] decreases expression
/ decreases reaction
/ increases degradation
protein 19557821
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] decreases expression
/ decreases reaction
protein 12672908
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 epigallocatechin gallate results in decreased expression of BCL2 protein decreases expression
protein 15657356
20149610
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 [arsenic trioxide co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 protein affects cotreatment
/ decreases expression
protein 20950636
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 18348186
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of BCL2L1 mRNA alternative form] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 18348186
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 [Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form affects cotreatment
/ decreases expression
mRNA 18348186
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 [Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of BCL2L1 mRNA alternative form affects cotreatment
/ increases expression
mRNA 18348186
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 tautomycin inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 18348186
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 tautomycin inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of BCL2L1 mRNA alternative form] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 18348186
C045651 602 BCL3
BCL4
D19S37
B-cell CLL/lymphoma 3 epigallocatechin gallate results in increased expression of BCL3 mRNA increases expression
mRNA 22079256
C045651 602 BCL3
BCL4
D19S37
B-cell CLL/lymphoma 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BCL3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 604 BCL6
BCL5
BCL6A
LAZ3
ZBTB27
ZNF51
B-cell CLL/lymphoma 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BCL6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 605 BCL7A
BCL7
B-cell CLL/lymphoma 7A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BCL7A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 623 BDKRB1
B1BKR
B1R
BKB1R
BKR1
BRADYB1
bradykinin receptor B1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BDKRB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23299 BICD2
SMALED2
bA526D8.1
bicaudal D homolog 2 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BICD2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55909 BIN3
bridging integrator 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BIN3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 330 BIRC3
AIP1
API2
CIAP2
HAIP1
HIAP1
MALT2
MIHC
RNF49
c-IAP2
baculoviral IAP repeat containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BIRC3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 414899 BLID
BRCC2
BH3-like motif containing, cell death inducer [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BLID mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 644 BLVRA
BLVR
BVR
BVRA
biliverdin reductase A (EC:1.3.1.24) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BLVRA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55589 BMP2K
BIKE
BMP2 inducible kinase (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BMP2K mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 652 BMP4
BMP2B
BMP2B1
MCOPS6
OFC11
ZYME
bone morphogenetic protein 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BMP4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 168667 BMPER
CRIM3
CV-2
CV2
BMP binding endothelial regulator [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BMPER mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 657 BMPR1A
10q23del
ACVRLK3
ALK3
CD292
SKR5
bone morphogenetic protein receptor, type IA (EC:2.7.11.30) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BMPR1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51027 BOLA1
bolA family member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BOLA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79866 BORA
C13orf34
bora, aurora kinase A activator [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BORA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 669 BPGM
DPGM
2,3-bisphosphoglycerate mutase (EC:3.1.3.13 5.4.2.4 5.4.2.11) epigallocatechin gallate results in decreased expression of BPGM mRNA decreases expression
mRNA 16084531
C045651 672 BRCA1
BRCAI
BRCC1
BROVCA1
IRIS
PNCA4
PPP1R53
PSCP
RNF53
breast cancer 1, early onset [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRCA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 675 BRCA2
BRCC2
BROVCA2
FACD
FAD
FAD1
FANCB
FANCD
FANCD1
GLM3
PNCA2
breast cancer 2, early onset [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRCA2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23774 BRD1
BRL
BRPF1
BRPF2
bromodomain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BRD1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 83990 BRIP1
BACH1
FANCJ
OF
BRCA1 interacting protein C-terminal helicase 1 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRIP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27154 BRPF3
bromodomain and PHD finger containing, 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BRPF3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 254065 BRWD3
BRODL
MRX93
bromodomain and WD repeat domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRWD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 689 BTF3
BETA-NAC
BTF3a
BTF3b
NACB
basic transcription factor 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BTF3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 91408 BTF3L4
basic transcription factor 3-like 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BTF3L4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 694 BTG1
B-cell translocation gene 1, anti-proliferative epigallocatechin gallate results in decreased expression of BTG1 mRNA decreases expression
mRNA 16084531
C045651 694 BTG1
B-cell translocation gene 1, anti-proliferative [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BTG1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 11119 BTN3A1
BT3.1
BTF5
CD277
butyrophilin, subfamily 3, member A1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BTN3A1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11118 BTN3A2
BT3.2
BTF4
CD277
butyrophilin, subfamily 3, member A2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BTN3A2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10384 BTN3A3
BTF3
butyrophilin, subfamily 3, member A3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BTN3A3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8945 BTRC
BETA-TRCP
FBW1A
FBXW1
FBXW1A
FWD1
bTrCP
bTrCP1
betaTrCP
beta-transducin repeat containing E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BTRC mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 699 BUB1
BUB1A
BUB1L
hBUB1
BUB1 mitotic checkpoint serine/threonine kinase (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BUB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8896 BUD31
Cwc14
EDG-2
EDG2
G10
YCR063W
fSAP17
BUD31 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BUD31 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 56652 C10orf2
ATXN8
IOSCA
MTDPS7
PEO
PEO1
PEOA3
SANDO
SCA8
TWINL
chromosome 10 open reading frame 2 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C10ORF2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51501 C11orf73
HSPC179
Hikeshi
L7RN6
OPI10
chromosome 11 open reading frame 73 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C11ORF73 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55017 C14orf119
chromosome 14 open reading frame 119 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C14ORF119 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56905 C15orf39
chromosome 15 open reading frame 39 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C15ORF39 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 84529 C15orf41
HH114
chromosome 15 open reading frame 41 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C15ORF41 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84419 C15orf48
FOAP-11
NMES1
chromosome 15 open reading frame 48 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C15ORF48 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29035 C16orf72
PRO0149
chromosome 16 open reading frame 72 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C16ORF72 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 125144 C17orf76-AS1
C17orf45
NCRNA00188
TSAP19
FAM211A-AS1
C17orf76 antisense RNA 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C17ORF76-AS1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 56913 C1GALT1
C1GALT
T-synthase
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 (EC:2.4.1.122) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C1GALT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55732 C1orf112
RP1-97P20.1
chromosome 1 open reading frame 112 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C1ORF112 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 128346 C1orf162
chromosome 1 open reading frame 162 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C1ORF162 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 81563 C1orf21
PIG13
chromosome 1 open reading frame 21 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C1ORF21 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 148523 C1orf51
chromosome 1 open reading frame 51 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C1ORF51 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 148423 C1orf52
RP11-234D19.1
gm117
chromosome 1 open reading frame 52 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C1ORF52 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9854 C2CD2L
TMEM24
C2CD2-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C2CD2L mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26005 C2CD3
C2 calcium-dependent domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C2CD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9847 C2CD5
CDP138
KIAA0528
C2 calcium-dependent domain containing 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C2CD5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 60526 C2orf43
chromosome 2 open reading frame 43 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C2ORF43 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57415 C3orf14
chromosome 3 open reading frame 14 epigallocatechin gallate results in decreased expression of C3ORF14 mRNA decreases expression
mRNA 22079256
C045651 57415 C3orf14
chromosome 3 open reading frame 14 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C3ORF14 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 152078 C3orf55
chromosome 3 open reading frame 55 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C3ORF55 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54969 C4orf27
chromosome 4 open reading frame 27 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C4ORF27 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64417 C5orf28
chromosome 5 open reading frame 28 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C5ORF28 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 65250 C5orf42
JBTS17
chromosome 5 open reading frame 42 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C5ORF42 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 100425666 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C6ORF125 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51250 C6orf203
PRED31
RP11-59I9.1
chromosome 6 open reading frame 203 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C6ORF203 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57827 C6orf47
D6S53E
G4
NG34
chromosome 6 open reading frame 47 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C6ORF47 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 50854 C6orf48
D6S57
G8
chromosome 6 open reading frame 48 epigallocatechin gallate results in decreased expression of C6ORF48 mRNA decreases expression
mRNA 22079256
C045651 50854 C6orf48
D6S57
G8
chromosome 6 open reading frame 48 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C6ORF48 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 78996 C7orf49
MRI
chromosome 7 open reading frame 49 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C7ORF49 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 138724 C9orf131
chromosome 9 open reading frame 131 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C9ORF131 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 84688 C9orf24
CBE1
NYD-SP22
SMRP1
bA573M23.4
chromosome 9 open reading frame 24 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C9ORF24 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 84909 C9orf3
AOPEP
AP-O
APO
C90RF3
ONPEP
chromosome 9 open reading frame 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C9ORF3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 138199 C9orf41
chromosome 9 open reading frame 41 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C9ORF41 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 782 CACNB1
CAB1
CACNLB1
CCHLB1
calcium channel, voltage-dependent, beta 1 subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CACNB1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 817 CAMK2D
CAMKD
calcium/calmodulin-dependent protein kinase II delta (EC:2.7.11.17) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CAMK2D mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79823 CAMKMT
C2orf34
CLNMT
CaM_KMT
Cam
KMT
calmodulin-lysine N-methyltransferase (EC:2.1.1.60) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CAMKMT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 819 CAMLG
CAML
calcium modulating ligand [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CAMLG mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 65981 CAPRIN2
C1QDC1
EEG-1
EEG1
RNG140
caprin family member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CAPRIN2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22794 CASC3
BTZ
MLN51
cancer susceptibility candidate 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CASC3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 64921 CASD1
C7orf12
NBLA04196
CAS1 domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CASD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 834 CASP1
ICE
IL1BC
P45
caspase 1, apoptosis-related cysteine peptidase (EC:3.4.22.36) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CASP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [arsenic trioxide co-treated with epigallocatechin gallate] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 20950636
C045651 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) epigallocatechin gallate affects the cleavage of CASP3 protein affects cleavage
protein 15975156
C045651 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) epigallocatechin gallate analog results in increased cleavage of CASP3 protein increases cleavage
protein 16115949
C045651 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased cleavage of and results in increased activity of CASP3 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 12672908
15795422
C045651 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in increased cleavage of and results in increased activity of CASP3 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 22079256
C045651 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) epigallocatechin gallate results in increased activity of CASP3 protein increases activity
protein 15657356
15705601
15764647
C045651 839 CASP6
MCH2
caspase 6, apoptosis-related cysteine peptidase (EC:3.4.22.59) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CASP6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CASP8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) epigallocatechin gallate analog results in increased cleavage of CASP9 protein increases cleavage
protein 16115949
C045651 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) epigallocatechin gallate results in increased activity of CASP9 protein increases activity
protein 15764647
C045651 847 CAT
catalase (EC:1.11.1.6) CAT protein inhibits the reaction [epigallocatechin gallate analog results in decreased expression of BCL2 protein] decreases expression
/ decreases reaction
protein 16115949
C045651 847 CAT
catalase (EC:1.11.1.6) CAT protein inhibits the reaction [epigallocatechin gallate analog results in decreased expression of MCL1 protein] decreases expression
/ decreases reaction
protein 16115949
C045651 847 CAT
catalase (EC:1.11.1.6) CAT protein inhibits the reaction [epigallocatechin gallate analog results in increased abundance of Reactive Oxygen Species] decreases reaction
/ increases abundance
protein 16115949
C045651 858 CAV2
CAV
caveolin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CAV2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 868 CBLB
Cbl-b
RNF56
Cbl proto-oncogene B, E3 ubiquitin protein ligase epigallocatechin gallate results in increased expression of CBLB mRNA increases expression
mRNA 22079256
C045651 868 CBLB
Cbl-b
RNF56
Cbl proto-oncogene B, E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CBLB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79872 CBLL1
HAKAI
RNF188
Cbl proto-oncogene-like 1, E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CBLL1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8535 CBX4
NBP16
PC2
chromobox homolog 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CBX4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 25776 CBY1
C22orf2
CBY
HS508I15A
PGEA1
PIGEA-14
PIGEA14
arb1
chibby homolog 1 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CBY1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 200014 CC2D1B
coiled-coil and C2 domain containing 1B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CC2D1B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57545 CC2D2A
JBTS9
MKS6
coiled-coil and C2 domain containing 2A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CC2D2A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 388389 CCDC103
CILD17
PR46b
SMH
coiled-coil domain containing 103 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC103 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 202243 CCDC125
KENAE
coiled-coil domain containing 125 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC125 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90693 CCDC126
coiled-coil domain containing 126 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC126 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55610 CCDC132
coiled-coil domain containing 132 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC132 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 165055 CCDC138
coiled-coil domain containing 138 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC138 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 154467 CCDC167
C6orf129
HSPC265
coiled-coil domain containing 167 epigallocatechin gallate results in decreased expression of CCDC167 mRNA decreases expression
mRNA 22079256
C045651 154467 CCDC167
C6orf129
HSPC265
coiled-coil domain containing 167 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC167 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 343099 CCDC18
NY-SAR-41
dJ717I23.1
coiled-coil domain containing 18 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC18 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 374969 CCDC23
coiled-coil domain containing 23 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC23 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51134 CCDC41
Cep83
NY-REN-58
coiled-coil domain containing 41 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC41 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 100286684 epigallocatechin gallate results in decreased expression of CCDC5 mRNA decreases expression
mRNA 22079256
C045651 100286684 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84660 CCDC62
CT109
ERAP75
TSP-NY
coiled-coil domain containing 62 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCDC62 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 64925 CCDC71
coiled-coil domain containing 71 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC71 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84318 CCDC77
coiled-coil domain containing 77 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC77 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79080 CCDC86
coiled-coil domain containing 86 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCDC86 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55297 CCDC91
p56
coiled-coil domain containing 91 epigallocatechin gallate results in decreased expression of CCDC91 mRNA decreases expression
mRNA 22079256
C045651 55297 CCDC91
p56
coiled-coil domain containing 91 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC91 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54535 CCHCR1
C6orf18
HCR
SBP
coiled-coil alpha-helical rod protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCHCR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 epigallocatechin gallate results in decreased secretion of CCL2 protein decreases secretion
protein 20816778
C045651 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 891 CCNB1
CCNB
cyclin B1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCNB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57820 CCNB1IP1
C14orf18
HEI10
cyclin B1 interacting protein 1, E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCNB1IP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 epigallocatechin gallate results in decreased expression of CCND1 protein decreases expression
protein 15142168
C045651 899 CCNF
FBX1
FBXO1
cyclin F [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCNF mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 900 CCNG1
CCNG
cyclin G1 epigallocatechin gallate results in increased expression of CCNG1 mRNA increases expression
mRNA 18851785
C045651 900 CCNG1
CCNG
cyclin G1 epigallocatechin gallate results in increased expression of CCNG1 protein increases expression
protein 18851785
C045651 901 CCNG2
cyclin G2 epigallocatechin gallate results in increased expression of CCNG2 mRNA increases expression
mRNA 18851785
C045651 57018 CCNL1
ANIA6A
PRO1073
ania-6a
cyclin L1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCNL1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 905 CCNT2
CYCT2
cyclin T2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCNT2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 219771 CCNY
C10orf9
CBCP1
CCNX
CFP1
cyclin Y [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCNY mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25819 CCRN4L
CCR4L
NOC
CCR4 carbon catabolite repression 4-like (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCRN4L mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54462 CCSER2
FAM190B
Gcap14
KIAA1128
bA486O22.1
coiled-coil serine-rich protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCSER2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 929 CD14
CD14 molecule [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CD14 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23607 CD2AP
CMS
CD2-associated protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CD2AP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 965 CD58
LFA-3
LFA3
ag3
CD58 molecule [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CD58 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 993 CDC25A
CDC25A2
cell division cycle 25A (EC:3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CDC25A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 995 CDC25C
CDC25
PPP1R60
cell division cycle 25C (EC:3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC25C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 996 CDC27
ANAPC3
APC3
CDC27Hs
D0S1430E
D17S978E
HNUC
NUC2
cell division cycle 27 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC27 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10602 CDC42EP3
BORG2
CEP3
UB1
CDC42 effector protein (Rho GTPase binding) 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC42EP3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56990 CDC42SE2
SPEC2
CDC42 small effector 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC42SE2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79577 CDC73
C1orf28
HPTJT
HRPT2
HYX
cell division cycle 73 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC73 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83461 CDCA3
GRCC8
TOME-1
cell division cycle associated 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDCA3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1012 CDH13
CDHH
P105
cadherin 13 (EC:3.6.1.3) epigallocatechin gallate results in decreased expression of CDH13 mRNA decreases expression
mRNA 16084531
C045651 1019 CDK4
CMM3
PSK-J3
cyclin-dependent kinase 4 (EC:2.7.11.22) epigallocatechin gallate results in decreased expression of CDK4 protein decreases expression
protein 15142168
C045651 8851 CDK5R1
CDK5P35
CDK5R
NCK5A
p23
p25
p35
p35nck5a
cyclin-dependent kinase 5, regulatory subunit 1 (p35) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CDK5R1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55755 CDK5RAP2
C48
Cep215
MCPH3
CDK5 regulatory subunit associated protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDK5RAP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1021 CDK6
PLSTIRE
cyclin-dependent kinase 6 (EC:2.7.11.22) epigallocatechin gallate results in decreased expression of CDK6 protein decreases expression
protein 15142168
C045651 1021 CDK6
PLSTIRE
cyclin-dependent kinase 6 (EC:2.7.11.22) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDK6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6792 CDKL5
EIEE2
ISSX
STK9
cyclin-dependent kinase-like 5 (EC:2.7.11.22) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDKL5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A protein results in increased susceptibility to epigallocatechin gallate increases response to substance
protein 15764647
C045651 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) epigallocatechin gallate results in decreased expression of CDKN1A mRNA decreases expression
mRNA 18851785
C045651 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) epigallocatechin gallate results in increased expression of CDKN1A protein increases expression
protein 15764647
C045651 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) [Sulindac co-treated with epigallocatechin gallate] results in increased expression of CDKN1A mRNA affects cotreatment
/ increases expression
mRNA 12628509
C045651 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDKN1B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1029 CDKN2A
ARF
CDK4I
CDKN2
CMM2
INK4
INK4A
MLM
MTS-1
MTS1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
cyclin-dependent kinase inhibitor 2A epigallocatechin gallate results in decreased metabolism of CDKN2A promoter decreases metabolic processing
promoter 16037419
C045651 1029 CDKN2A
ARF
CDK4I
CDKN2
CMM2
INK4
INK4A
MLM
MTS-1
MTS1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
cyclin-dependent kinase inhibitor 2A epigallocatechin gallate results in decreased methylation of CDKN2A gene decreases methylation
gene 17683969
C045651 1029 CDKN2A
ARF
CDK4I
CDKN2
CMM2
INK4
INK4A
MLM
MTS-1
MTS1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
cyclin-dependent kinase inhibitor 2A epigallocatechin gallate results in decreased methylation of CDKN2A promoter decreases methylation
promoter 14633667
C045651 1029 CDKN2A
ARF
CDK4I
CDKN2
CMM2
INK4
INK4A
MLM
MTS-1
MTS1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
cyclin-dependent kinase inhibitor 2A epigallocatechin gallate results in increased expression of CDKN2A mRNA increases expression
mRNA 14633667
C045651 1029 CDKN2A
ARF
CDK4I
CDKN2
CMM2
INK4
INK4A
MLM
MTS-1
MTS1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
cyclin-dependent kinase inhibitor 2A epigallocatechin gallate results in increased expression of CDKN2A protein increases expression
protein 17683969
C045651 55602 CDKN2AIP
CARF
CDKN2A interacting protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CDKN2AIP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 50937 CDON
CDO
CDON1
HPE11
ORCAM
cell adhesion associated, oncogene regulated [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDON mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1052 CEBPD
C/EBP-delta
CELF
CRP3
NF-IL6-beta
CCAAT/enhancer binding protein (C/EBP), delta [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEBPD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1057 CELP
CELL
cell1
cell2
cell3
carboxyl ester lipase pseudogene [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CELP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1058 CENPA
CENP-A
CenH3
centromere protein A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CENPA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1062 CENPE
CENP-E
KIF10
PPP1R61
centromere protein E, 312kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CENPE mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2491 CENPI
CENP-I
FSHPRH1
LRPR1
Mis6
centromere protein I [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CENPI mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 401541 CENPP
CENP-P
centromere protein P [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CENPP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 201134 CEP112
CCDC46
MACOCO
centrosomal protein 112kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP112 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 145508 CEP128
C14orf145
C14orf61
LEDP/132
centrosomal protein 128kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP128 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9859 CEP170
FAM68A
KAB
KIAA0470
centrosomal protein 170kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP170 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80184 CEP290
3H11Ag
BBS14
CT87
JBTS5
LCA10
MKS4
NPHP6
POC3
SLSN6
rd16
centrosomal protein 290kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP290 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 95681 CEP41
JBTS15
TSGA14
centrosomal protein 41kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP41 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80321 CEP70
BITE
centrosomal protein 70kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP70 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10390 CEPT1
choline/ethanolamine phosphotransferase 1 (EC:2.7.8.2 2.7.8.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEPT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1070 CETN3
CDC31
CEN3
centrin, EF-hand protein, 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CETN3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 629 CFB
AHUS4
BF
BFD
CFAB
FB
FBI12
GBG
H2-Bf
PBF2
complement factor B (EC:3.4.21.47) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CFB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8837 CFLAR
CASH
CASP8AP1
CLARP
Casper
FLAME
FLAME-1
FLAME1
FLIP
I-FLICE
MRIT
c-FLIP
c-FLIPL
c-FLIPR
c-FLIPS
CASP8 and FADD-like apoptosis regulator [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CFLAR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79094 CHAC1
ChaC, cation transport regulator homolog 1 (E. coli) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHAC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 494143 CHAC2
ChaC, cation transport regulator homolog 2 (E. coli) epigallocatechin gallate results in decreased expression of CHAC2 mRNA decreases expression
mRNA 22079256
C045651 494143 CHAC2
ChaC, cation transport regulator homolog 2 (E. coli) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHAC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 118487 CHCHD1
C10orf34
C2360
MRP-S37
coiled-coil-helix-coiled-coil-helix domain containing 1 epigallocatechin gallate results in decreased expression of CHCHD1 mRNA decreases expression
mRNA 22079256
C045651 118487 CHCHD1
C10orf34
C2360
MRP-S37
coiled-coil-helix-coiled-coil-helix domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHCHD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84181 CHD6
CHD-6
CHD5
RIGB
chromodomain helicase DNA binding protein 6 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHD6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55636 CHD7
HH5
IS3
KAL5
chromodomain helicase DNA binding protein 7 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHD7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80205 CHD9
AD013
CReMM
KISH2
PRIC320
chromodomain helicase DNA binding protein 9 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHD9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79643 CHMP6
VPS20
charged multivesicular body protein 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHMP6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 50515 CHST11
C4ST
C4ST-1
C4ST1
HSA269537
carbohydrate (chondroitin 4) sulfotransferase 11 (EC:2.8.2.5) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHST11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51363 CHST15
BRAG
GALNAC4S-6ST
RP11-47G11.1
carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 (EC:2.8.2.33) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHST15 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55847 CISD1
C10orf70
ZCD1
mitoNEET
CDGSH iron sulfur domain 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CISD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25792 CIZ1
LSFR1
NP94
ZNF356
CDKN1A interacting zinc finger protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CIZ1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9793 CKAP5
CHTOG
MSPS
TOG
TOGp
ch-TOG
cytoskeleton associated protein 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CKAP5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1164 CKS2
CKSHS2
CDC28 protein kinase regulatory subunit 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CKS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23332 CLASP1
MAST1
cytoplasmic linker associated protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLASP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1366 CLDN7
CEPTRL2
CLDN-7
CPETRL2
Hs.84359
claudin-1
claudin 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLDN7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1195 CLK1
CLK
CLK/STY
STY
CDC-like kinase 1 (EC:2.7.12.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CLK1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1198 CLK3
PHCLK3
PHCLK3/152
CDC-like kinase 3 (EC:2.7.12.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CLK3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 79789 CLMN
calmin (calponin-like, transmembrane) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLMN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79827 CLMP
ACAM
ASAM
CSBM
CSBS
CXADR-like membrane protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLMP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9575 CLOCK
KAT13D
bHLHe8
clock circadian regulator (EC:2.3.1.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLOCK mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10978 CLP1
HEAB
hClp1
cleavage and polyadenylation factor I subunit 1 (EC:2.7.1.78) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CLP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 81570 CLPB
HSP78
SKD3
ClpB caseinolytic peptidase B homolog (E. coli) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLPB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8218 CLTCL1
CHC22
CLH22
CLTCL
CLTD
clathrin, heavy chain-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLTCL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55907 CMAS
CSS
cytidine monophosphate N-acetylneuraminic acid synthetase (EC:2.7.7.43) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CMAS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80790 CMIP
TCMIP
c-Maf inducing protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CMIP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22866 CNKSR2
CNK2
KSR2
MAGUIN
connector enhancer of kinase suppressor of Ras 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNKSR2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 154043 CNKSR3
MAGI1
CNKSR family member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNKSR3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26507 CNNM1
ACDP1
CLP-1
cyclin M1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNNM1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55571 CNOT11
C2orf29
CCR4-NOT transcription complex, subunit 11 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNOT11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4848 CNOT2
CDC36
NOT2
NOT2H
CCR4-NOT transcription complex, subunit 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNOT2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 246175 CNOT6L
CCR4b
CCR4-NOT transcription complex, subunit 6-like (EC:3.1.13.4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNOT6L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54875 CNTLN
C9orf101
C9orf39
RP11-340N12.1
bA340N12.1
centlein, centrosomal protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNTLN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 28958 COA3
CCDC56
MITRAC12
cytochrome c oxidase assembly factor 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COA3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 388753 COA6
C1orf31
cytochrome c oxidase assembly factor 6 homolog (S. cerevisiae) epigallocatechin gallate results in decreased expression of COA6 mRNA decreases expression
mRNA 22079256
C045651 388753 COA6
C1orf31
cytochrome c oxidase assembly factor 6 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COA6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22796 COG2
LDLC
component of oligomeric golgi complex 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COG2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57511 COG6
CDG2L
COD2
SHNS
component of oligomeric golgi complex 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COG6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 91949 COG7
CDG2E
component of oligomeric golgi complex 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COG7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1277 COL1A1
OI4
collagen, type I, alpha 1 epigallocatechin gallate results in increased expression of COL1A1 mRNA increases expression
mRNA 20706672
C045651 1282 COL4A1
HANAC
ICH
POREN1
arresten
collagen, type IV, alpha 1 epigallocatechin gallate results in decreased expression of COL4A1 mRNA decreases expression
mRNA 16084531
C045651 1291 COL6A1
OPLL
collagen, type VI, alpha 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of COL6A1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 27235 COQ2
CL640
COQ10D1
MSA1
coenzyme Q2 4-hydroxybenzoate polyprenyltransferase (EC:2.5.1.39) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COQ2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84274 COQ5
coenzyme Q5 homolog, methyltransferase (S. cerevisiae) (EC:2.1.1.201) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COQ5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57017 COQ9
C16orf49
COQ10D5
coenzyme Q9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COQ9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23406 COTL1
CLP
coactosin-like 1 (Dictyostelium) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of COTL1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4512 COX1
COI
MTCO1
MT-CO1
cytochrome c oxidase subunit I epigallocatechin gallate results in increased expression of COX1 mRNA increases expression
mRNA 20706672
C045651 10063 COX17
COX17 cytochrome c oxidase copper chaperone epigallocatechin gallate results in decreased expression of COX17 mRNA decreases expression
mRNA 22079256
C045651 10063 COX17
COX17 cytochrome c oxidase copper chaperone [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COX17 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1359 CPA3
MC-CPA
carboxypeptidase A3 (mast cell) (EC:3.4.17.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPA3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1363 CPE
carboxypeptidase E (EC:3.4.17.10) epigallocatechin gallate results in decreased expression of CPE mRNA decreases expression
mRNA 16084531
C045651 132864 CPEB2
CPE-BP2
CPEB-2
hCPEB-2
cytoplasmic polyadenylation element binding protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPEB2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 144402 CPNE8
copine VIII [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPNE8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51692 CPSF3
CPSF-73
CPSF73
cleavage and polyadenylation specific factor 3, 73kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPSF3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8738 CRADD
MRT34
RAIDD
CASP2 and RIPK1 domain containing adaptor with death domain epigallocatechin gallate results in decreased expression of CRADD mRNA decreases expression
mRNA 16084531
C045651 8738 CRADD
MRT34
RAIDD
CASP2 and RIPK1 domain containing adaptor with death domain [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CRADD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1385 CREB1
CREB
cAMP responsive element binding protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CREB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90993 CREB3L1
OASIS
cAMP responsive element binding protein 3-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CREB3L1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 153222 CREBRF
C5orf41
LRF
CREB3 regulatory factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CREBRF mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 58487 CREBZF
SMILE
ZF
CREB/ATF bZIP transcription factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CREBZF mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 147081 CRHR1-IT1
C17orf69
CRHR1 intronic transcript 1 (non-protein coding) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CRHR1-IT1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54677 CROT
COT
carnitine O-octanoyltransferase (EC:2.3.1.137) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CROT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1410 CRYAB
CMD1II
CRYA2
CTPP2
CTRCT16
HSPB5
MFM2
crystallin, alpha B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CRYAB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1415 CRYBB2
CCA2
CRYB2
CRYB2A
CTRCT3
D22S665
crystallin, beta B2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CRYBB2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9946 CRYZL1
4P11
QOH-1
crystallin, zeta (quinone reductase)-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CRYZL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1459 CSNK2A2
CK2A2
CSNK2A1
casein kinase 2, alpha prime polypeptide (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CSNK2A2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1464 CSPG4
HMW-MAA
MCSP
MCSPG
MEL-CSPG
MSK16
NG2
chondroitin sulfate proteoglycan 4 epigallocatechin gallate results in increased expression of CSPG4 mRNA increases expression
mRNA 22079256
C045651 1464 CSPG4
HMW-MAA
MCSP
MCSPG
MEL-CSPG
MSK16
NG2
chondroitin sulfate proteoglycan 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CSPG4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57325 CSRP2BP
ATAC2
CRP2BP
KAT14
PRO1194
dJ717M23.1
CSRP2 binding protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CSRP2BP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9811 CTIF
Gm672
KIAA0427
CBP80/20-dependent translation initiation factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CTIF mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1499 CTNNB1
CTNNB
MRD19
armadillo
catenin (cadherin-associated protein), beta 1, 88kDa epigallocatechin gallate results in decreased expression of CTNNB1 mRNA decreases expression
mRNA 16968065
C045651 1499 CTNNB1
CTNNB
MRD19
armadillo
catenin (cadherin-associated protein), beta 1, 88kDa epigallocatechin gallate results in decreased expression of CTNNB1 protein decreases expression
protein 16968065
C045651 1499 CTNNB1
CTNNB
MRD19
armadillo
catenin (cadherin-associated protein), beta 1, 88kDa epigallocatechin gallate results in decreased localization of CTNNB1 protein decreases localization
protein 16968065
C045651 1499 CTNNB1
CTNNB
MRD19
armadillo
catenin (cadherin-associated protein), beta 1, 88kDa epigallocatechin gallate results in decreased phosphorylation of CTNNB1 protein decreases phosphorylation
protein 16968065
C045651 1497 CTNS
CTNS-LSB
PQLC4
cystinosin, lysosomal cystine transporter [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CTNS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51797 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CTPS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56474 CTPS2
CTP synthase 2 (EC:6.3.4.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CTPS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2919 CXCL1
FSP
GRO1
GROa
MGSA
MGSA-a
NAP-3
SCYB1
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CXCL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3627 CXCL10
C7
IFI10
INP10
IP-10
SCYB10
crg-2
gIP-10
mob-1
chemokine (C-X-C motif) ligand 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CXCL10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51523 CXXC5
CF5
RINF
WID
CXXC finger protein 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CXXC5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11068 CYB561D2
101F6
TSP10
cytochrome b561 family, member D2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CYB561D2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 124637 CYB5D1
cytochrome b5 domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CYB5D1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic epigallocatechin gallate affects the localization of CYCS protein affects localization
protein 15657356
C045651 114757 CYGB
HGB
STAP
cytoglobin epigallocatechin gallate results in decreased expression of CYGB mRNA decreases expression
mRNA 20706672
C045651 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) epigallocatechin gallate inhibits the reaction [[Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA] affects binding
/ decreases reaction
/ increases activity
/ increases expression
mRNA 11064004
C045651 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] decreases reaction
/ increases expression
mRNA 14558788
C045651 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) epigallocatechin gallate results in decreased expression of CYP1A1 mRNA decreases expression
mRNA 20816778
C045651 1545 CYP1B1
CP1B
CYPIB1
GLC3A
P4501B1
cytochrome P450, family 1, subfamily B, polypeptide 1 (EC:1.14.14.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CYP1B1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1594 CYP27B1
CP2B
CYP1
CYP1alpha
CYP27B
P450c1
PDDR
VDD1
VDDR
VDDRI
VDR
cytochrome P450, family 27, subfamily B, polypeptide 1 (EC:1.14.13.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CYP27B1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9265 CYTH3
ARNO3
GRP1
PSCD3
cytohesin 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CYTH3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23002 DAAM1
dishevelled associated activator of morphogenesis 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DAAM1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1601 DAB2
DOC-2
DOC2
Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DAB2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1612 DAPK1
DAPK
death-associated protein kinase 1 (EC:2.7.11.1) epigallocatechin gallate results in decreased expression of DAPK1 mRNA decreases expression
mRNA 12628509
C045651 1612 DAPK1
DAPK
death-associated protein kinase 1 (EC:2.7.11.1) epigallocatechin gallate results in increased expression of DAPK1 mRNA increases expression
mRNA 22079256
C045651 1612 DAPK1
DAPK
death-associated protein kinase 1 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DAPK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1613 DAPK3
ZIP
ZIPK
death-associated protein kinase 3 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DAPK3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55157 DARS2
ASPRS
LBSL
MT-ASPRS
RP3-383J4.2
aspartyl-tRNA synthetase 2, mitochondrial (EC:6.1.1.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DARS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 285761 DCBLD1
dJ94G16.1
discoidin, CUB and LCCL domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DCBLD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 166614 DCLK2
CL2
CLICK-II
CLICK2
CLIK2
DCAMKL2
DCDC3
DCDC3B
DCK2
doublecortin-like kinase 2 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DCLK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9937 DCLRE1A
PSO2
SNM1
SNM1A
DNA cross-link repair 1A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DCLRE1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23142 DCUN1D4
DCN1, defective in cullin neddylation 1, domain containing 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DCUN1D4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 100286728 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DDEF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80821 DDHD1
PA-PLA1
PAPLA1
SPG28
DDHD domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DDHD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[epigallocatechin gallate co-treated with celecoxib] results in increased expression of DDIT3 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 16463383
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[epigallocatechin gallate co-treated with celecoxib] results in increased expression of DDIT3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 16463383
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 [epigallocatechin gallate co-treated with celecoxib] results in increased expression of DDIT3 mRNA affects cotreatment
/ increases expression
mRNA 16463383
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 [epigallocatechin gallate co-treated with celecoxib] results in increased expression of DDIT3 protein affects cotreatment
/ increases expression
protein 16463383
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 epigallocatechin gallate results in increased expression of DDIT3 mRNA increases expression
mRNA 16084531
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DDIT3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 [Sulindac co-treated with epigallocatechin gallate] results in increased expression of DDIT3 mRNA affects cotreatment
/ increases expression
mRNA 12628509
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 U 0126 inhibits the reaction [[epigallocatechin gallate co-treated with celecoxib] results in increased expression of DDIT3 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 16463383
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 U 0126 inhibits the reaction [[epigallocatechin gallate co-treated with celecoxib] results in increased expression of DDIT3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 16463383
C045651 1662 DDX10
HRH-J8
DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DDX10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23586 DDX58
RIG-I
RIGI
RLR-1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DDX58 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55601 DDX60
DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DDX60 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 163259 DENND2C
dJ1156J9.1
DENN/MADD domain containing 2C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DENND2C mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 79961 DENND2D
DENN/MADD domain containing 2D [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND2D mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22898 DENND3
DENN/MADD domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10260 DENND4A
IRLB
MYCPBP
DENN/MADD domain containing 4A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND4A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55667 DENND4C
C9orf55
C9orf55B
bA513M16.3
DENN/MADD domain containing 4C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND4C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 201627 DENND6A
AFI1A
FAM116A
DENN/MADD domain containing 6A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND6A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8562 DENR
DRP
DRP1
SMAP-3
density-regulated protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 120863 DEPDC4
DEP.4
DEP domain containing 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DEPDC4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 91614 DEPDC7
TR2
dJ85M6.4
DEP domain containing 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DEPDC7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55070 DET1
de-etiolated homolog 1 (Arabidopsis) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DET1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1687 DFNA5
ICERE-1
deafness, autosomal dominant 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DFNA5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8527 DGKD
DGKdelta
dgkd-2
diacylglycerol kinase, delta 130kDa (EC:2.7.1.107) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DGKD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 160851 DGKH
DGKeta
diacylglycerol kinase, eta (EC:2.7.1.107) epigallocatechin gallate results in increased expression of DGKH mRNA increases expression
mRNA 22079256
C045651 160851 DGKH
DGKeta
diacylglycerol kinase, eta (EC:2.7.1.107) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DGKH mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1719 DHFR
DHFRP1
DYR
dihydrofolate reductase (EC:1.5.1.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DHFR mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55760 DHX32
DDX32
DHLP1
DEAH (Asp-Glu-Ala-His) box polypeptide 32 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DHX32 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 60625 DHX35
C20orf15
DDX35
KAIA0875
DEAH (Asp-Glu-Ala-His) box polypeptide 35 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DHX35 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90957 DHX57
DDX57
DEAH (Asp-Glu-Ala-Asp/His) box polypeptide 57 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DHX57 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56616 DIABLO
DFNA64
SMAC
diablo, IAP-binding mitochondrial protein epigallocatechin gallate analog affects the localization of DIABLO protein affects localization
protein 16115949
C045651 81624 DIAPH3
AN
AUNA1
DIA2
DRF3
NSDAN
diap3
mDia2
diaphanous-related formin 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIAPH3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 445162 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIMT1L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1734 DIO2
5DII
D2
DIOII
SelY
TXDI2
deiodinase, iodothyronine, type II (EC:1.97.1.10) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIO2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23181 DIP2A
C21orf106
DIP2
DIP2 disco-interacting protein 2 homolog A (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIP2A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57609 DIP2B
DIP2 disco-interacting protein 2 homolog B (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIP2B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 115752 DIS3L
DIS3L1
DIS3 mitotic control homolog (S. cerevisiae)-like (EC:3.1.13.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIS3L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84976 DISP1
DISPA
dispatched homolog 1 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DISP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85458 DIXDC1
CCD1
DIX domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIXDC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22943 DKK1
DKK-1
SK
dickkopf WNT signaling pathway inhibitor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DKK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1738 DLD
DLDD
DLDH
E3
GCSL
LAD
PHE3
dihydrolipoamide dehydrogenase (EC:1.8.1.4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8847 DLEU2
1B4
BCMSUN
DLB2
LEU2
LINC00022
MIR15AHG
NCRNA00022
RFP2OS
TRIM13OS
deleted in lymphocytic leukemia 2 (non-protein coding) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLEU2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1739 DLG1
DLGH1
SAP-97
SAP97
dJ1061C18.1.1
hdlg
discs, large homolog 1 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLG1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9787 DLGAP5
DLG7
HURP
discs, large (Drosophila) homolog-associated protein 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLGAP5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 65989 DLK2
DLK-2
EGFL9
delta-like 2 homolog (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54567 DLL4
hdelta2
delta-like 4 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DLL4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55929 DMAP1
DNMAP1
DNMTAP1
EAF2
MEAF2
SWC4
DNA methyltransferase 1 associated protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DMAP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1657 DMXL1
Dmx-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DMXL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23312 DMXL2
RC3
Dmx-like 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DMXL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1763 DNA2
DNA2L
PEOA6
hDNA2
DNA replication helicase/nuclease 2 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNA2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55172 DNAAF2
C14orf104
CILD10
KTU
PF13
dynein, axonemal, assembly factor 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAAF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11080 DNAJB4
DNAJW
DjB4
HLJ1
DnaJ (Hsp40) homolog, subfamily B, member 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJB4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25822 DNAJB5
Hsc40
DnaJ (Hsp40) homolog, subfamily B, member 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJB5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4189 DNAJB9
ERdj4
MDG-1
MDG1
MST049
MSTP049
DnaJ (Hsp40) homolog, subfamily B, member 9 epigallocatechin gallate results in increased expression of DNAJB9 mRNA increases expression
mRNA 16084531
C045651 23317 DNAJC13
RME8
DnaJ (Hsp40) homolog, subfamily C, member 13 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJC13 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85406 DNAJC14
DNAJ
DRIP78
HDJ3
LIP6
DnaJ (Hsp40) homolog, subfamily C, member 14 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJC14 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 131118 DNAJC19
PAM18
TIM14
TIMM14
DnaJ (Hsp40) homolog, subfamily C, member 19 epigallocatechin gallate results in decreased expression of DNAJC19 mRNA decreases expression
mRNA 22079256
C045651 131118 DNAJC19
PAM18
TIM14
TIMM14
DnaJ (Hsp40) homolog, subfamily C, member 19 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJC19 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54943 DNAJC28
C21orf55
C21orf78
DnaJ (Hsp40) homolog, subfamily C, member 28 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJC28 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 144132 DNHD1
C11orf47
CCDC35
DHCD1
DNHD1L
dynein heavy chain domain 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DNHD1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26052 DNM3
Dyna_III
dynamin 3 (EC:3.6.5.5) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNM3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1786 DNMT1
ADCADN
AIM
CXXC9
DNMT
HSN1E
MCMT
DNA (cytosine-5-)-methyltransferase 1 (EC:2.1.1.37) epigallocatechin gallate binds to and results in decreased activity of DNMT1 protein affects binding
/ decreases activity
protein 14633667
C045651 1786 DNMT1
ADCADN
AIM
CXXC9
DNMT
HSN1E
MCMT
DNA (cytosine-5-)-methyltransferase 1 (EC:2.1.1.37) epigallocatechin gallate results in decreased activity of DNMT1 protein decreases activity
protein 16037419
C045651 1786 DNMT1
ADCADN
AIM
CXXC9
DNMT
HSN1E
MCMT
DNA (cytosine-5-)-methyltransferase 1 (EC:2.1.1.37) Magnesium promotes the reaction [epigallocatechin gallate results in decreased activity of DNMT1 protein] decreases activity
/ increases reaction
protein 16037419
C045651 1789 DNMT3B
ICF
ICF1
M.HsaIIIB
DNA (cytosine-5-)-methyltransferase 3 beta (EC:2.1.1.37) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNMT3B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23549 DNPEP
ASPEP
DAP
aspartyl aminopeptidase (EC:3.4.11.21) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNPEP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 116092 DNTTIP1
C20orf167
Tdif1
dJ447F3.4
deoxynucleotidyltransferase, terminal, interacting protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNTTIP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 30836 DNTTIP2
ERBP
FCF2
HSU15552
LPTS-RP2
TdIF2
deoxynucleotidyltransferase, terminal, interacting protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DNTTIP2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55619 DOCK10
DRIP2
Nbla10300
ZIZ3
dedicator of cytokinesis 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOCK10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 139818 DOCK11
ACG
ZIZ2
bB128O4.1
dedicator of cytokinesis 11 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOCK11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85440 DOCK7
ZIR2
dedicator of cytokinesis 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOCK7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23348 DOCK9
ZIZ1
ZIZIMIN1
dedicator of cytokinesis 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOCK9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1796 DOK1
P62DOK
docking protein 1, 62kDa (downstream of tyrosine kinase 1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9980 DOPEY2
21orf5
C21orf5
dopey family member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOPEY2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 89978 DPH6
ATPBD4
diphthamine biosynthesis 6 (EC:6.3.1.14) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DPH6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1803 DPP4
ADABP
ADCP2
CD26
DPPIV
TP103
dipeptidyl-peptidase 4 (EC:3.4.14.5) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DPP4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55332 DRAM1
DRAM
DNA-damage regulated autophagy modulator 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DRAM1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1813 DRD2
D2DR
D2R
dopamine receptor D2 epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] affects binding
/ decreases reaction
/ increases abundance
/ increases activity
protein 17958328
C045651 79075 DSCC1
DCC1
DNA replication and sister chromatid cohesion 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DSCC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29940 DSE
DSEP
DSEPI
SART-2
SART2
dermatan sulfate epimerase (EC:5.1.3.19) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DSE mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1830 DSG3
CDHF6
PVA
desmoglein 3 epigallocatechin gallate results in decreased expression of DSG3 mRNA decreases expression
mRNA 20706672
C045651 667 DST
BP240
BPA
BPAG1
CATX-15
CATX15
D6S1101
DMH
DT
EBSB2
HSAN6
MACF2
dystonin [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DST mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 112487 DTD2
C14orf126
D-tyrosyl-tRNA deacylase 2 (putative) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DTD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84062 DTNBP1
BLOC1S8
DBND
HPS7
My031
SDY
dystrobrevin binding protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DTNBP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 285605 DTWD2
DTW domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DTWD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1841 DTYMK
CDC8
PP3731
TMPK
TYMK
deoxythymidylate kinase (thymidylate kinase) (EC:2.7.4.9) epigallocatechin gallate results in decreased expression of DTYMK mRNA decreases expression
mRNA 18851785
C045651 54920 DUS2
DUS2L
SMM1
URLC8
dihydrouridine synthase 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DUS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1846 DUSP4
HVH2
MKP-2
MKP2
TYP
dual specificity phosphatase 4 (EC:3.1.3.16 3.1.3.48) epigallocatechin gallate results in increased expression of DUSP4 mRNA increases expression
mRNA 16084531
C045651 1847 DUSP5
DUSP
HVH3
dual specificity phosphatase 5 (EC:3.1.3.16 3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DUSP5 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1848 DUSP6
HH19
MKP3
PYST1
dual specificity phosphatase 6 (EC:3.1.3.16 3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DUSP6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1849 DUSP7
MKPX
PYST2
dual specificity phosphatase 7 (EC:3.1.3.16 3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DUSP7 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1850 DUSP8
C11orf81
HB5
HVH-5
HVH8
dual specificity phosphatase 8 (EC:3.1.3.16 3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DUSP8 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6993 DYNLT1
CW-1
TCTEL1
tctex-1
dynein, light chain, Tctex-type 1 epigallocatechin gallate results in decreased expression of DYNLT1 mRNA decreases expression
mRNA 22079256
C045651 6993 DYNLT1
CW-1
TCTEL1
tctex-1
dynein, light chain, Tctex-type 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DYNLT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1859 DYRK1A
DYRK
DYRK1
HP86
MNB
MNBH
MRD7
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (EC:2.7.12.1) epigallocatechin gallate results in decreased activity of DYRK1A protein decreases activity
protein 12534346
C045651 9666 DZIP3
PPP1R66
UURF2
hRUL138
DAZ interacting zinc finger protein 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DZIP3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85403 EAF1
ELL associated factor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EAF1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9166 EBAG9
EB9
PDAF
estrogen receptor binding site associated, antigen, 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EBAG9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1889 ECE1
ECE
endothelin converting enzyme 1 (EC:3.4.24.71) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ECE1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1893 ECM1
URBWD
extracellular matrix protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ECM1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1894 ECT2
ARHGEF31
epithelial cell transforming sequence 2 oncogene [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ECT2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80267 EDEM3
C1orf22
ER degradation enhancer, mannosidase alpha-like 3 (EC:3.2.1.113) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EDEM3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1906 EDN1
ET1
HDLCQ7
PPET1
endothelin 1 epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased expression of EDN1 mRNA] decreases reaction
/ increases expression
mRNA 20021702
C045651 1906 EDN1
ET1
HDLCQ7
PPET1
endothelin 1 epigallocatechin gallate results in decreased expression of EDN1 mRNA decreases expression
mRNA 20021702
C045651 1910 EDNRB
ABCDS
ET-B
ET-BR
ETB
ETBR
ETRB
HSCR
HSCR2
WS4A
endothelin receptor type B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EDNRB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8411 EEA1
MST105
MSTP105
ZFYVE2
early endosome antigen 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EEA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1915 EEF1A1
CCS-3
CCS3
EE1A1
EEF-1
EEF1A
EF-Tu
EF1A
GRAF-1EF
HNGC:16303
LENG7
PTI1
eEF1A-1
eukaryotic translation elongation factor 1 alpha 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EEF1A1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 29904 EEF2K
HSU93850
eEF-2K
eukaryotic elongation factor-2 kinase (EC:2.7.11.20) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EEF2K mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 114327 EFHC1
dJ304B14.2
EF-hand domain (C-terminal) containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFHC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1942 EFNA1
B61
ECKLG
EFL1
EPLG1
LERK-1
LERK1
TNFAIP4
ephrin-A1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFNA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1945 EFNA4
EFL4
EPLG4
LERK4
ephrin-A4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFNA4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1946 EFNA5
AF1
EFL5
EPLG7
GLC1M
LERK7
RAGS
ephrin-A5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFNA5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1948 EFNB2
EPLG5
HTKL
Htk-L
LERK5
ephrin-B2 epigallocatechin gallate results in decreased expression of EFNB2 mRNA decreases expression
mRNA 16084531
C045651 1948 EFNB2
EPLG5
HTKL
Htk-L
LERK5
ephrin-B2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EFNB2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23167 EFR3A
EFR3 homolog A (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFR3A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22979 EFR3B
KIAA0953
EFR3 homolog B (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFR3B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79631 EFTUD1
FAM42A
HsT19294
RIA1
elongation factor Tu GTP binding domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFTUD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1950 EGF
HOMG4
URG
epidermal growth factor epigallocatechin gallate inhibits the reaction [EGF protein binds to EGFR protein] affects binding
/ decreases reaction
protein 17616711
C045651 1950 EGF
HOMG4
URG
epidermal growth factor epigallocatechin gallate inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]] affects binding
/ decreases reaction
/ increases reaction
protein 17616711
C045651 1950 EGF
HOMG4
URG
epidermal growth factor epigallocatechin gallate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] decreases reaction
/ increases phosphorylation
protein 17616711
C045651 1950 EGF
HOMG4
URG
epidermal growth factor epigallocatechin gallate results in decreased expression of EGF mRNA decreases expression
mRNA 20346928
20706672
C045651 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) epigallocatechin gallate inhibits the reaction [EGF protein binds to EGFR protein] affects binding
/ decreases reaction
protein 17616711
C045651 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) epigallocatechin gallate inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]] affects binding
/ decreases reaction
/ increases reaction
protein 17616711
C045651 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) epigallocatechin gallate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] decreases reaction
/ increases phosphorylation
protein 17616711
C045651 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) epigallocatechin gallate results in increased expression of EGFR mRNA increases expression
mRNA 22079256
C045651 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EGFR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) [Raloxifene co-treated with epigallocatechin gallate] results in decreased phosphorylation of EGFR protein affects cotreatment
/ decreases phosphorylation
protein 18371987
C045651 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in increased expression of EGR1 mRNA] decreases reaction
/ increases expression
mRNA 22079256
C045651 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 epigallocatechin gallate results in increased expression of EGR1 mRNA increases expression
mRNA 22079256
C045651 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EGR1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23301 EHBP1
HPC12
NACSIN
EH domain binding protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EHBP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1962 EHHADH
ECHD
L-PBE
LBFP
LBP
PBFE
enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase (EC:1.1.1.35 5.3.3.8 4.2.1.17) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EHHADH mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79813 EHMT1
EUHMTASE1
Eu-HMTase1
FP13812
GLP
GLP1
KMT1D
bA188C12.1
euchromatic histone-lysine N-methyltransferase 1 (EC:2.1.1.43) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EHMT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 440275 EIF2AK4
GCN2
eukaryotic translation initiation factor 2 alpha kinase 4 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EIF2AK4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1968 EIF2S3
EIF2
EIF2G
EIF2gamma
eIF-2gA
eukaryotic translation initiation factor 2, subunit 3 gamma, 52kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EIF2S3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1974 EIF4A2
BM-010
DDX2B
EIF4A
EIF4F
eIF-4A-II
eIF4A-II
eukaryotic translation initiation factor 4A2 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EIF4A2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1975 EIF4B
EIF-4B
PRO1843
eukaryotic translation initiation factor 4B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EIF4B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55520 ELAC1
D29
elaC ribonuclease Z 1 (EC:3.1.26.11) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELAC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1993 ELAVL2
HEL-N1
HELN1
HUB
ELAV like neuron-specific RNA binding protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELAVL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1997 ELF1
E74-like factor 1 (ets domain transcription factor) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2002 ELK1
ELK1, member of ETS oncogene family [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ELK1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 22936 ELL2
elongation factor, RNA polymerase II, 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84337 ELOF1
ELF1
elongation factor 1 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ELOF1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 64834 ELOVL1
Ssc1
ELOVL fatty acid elongase 1 (EC:2.3.1.199) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELOVL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54898 ELOVL2
SSC2
ELOVL fatty acid elongase 2 (EC:2.3.1.199) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELOVL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26610 ELP4
C11orf19
PAX6NEB
PAXNEB
dJ68P15A.1
elongator acetyltransferase complex subunit 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELP4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9694 EMC2
KIAA0103
TTC35
ER membrane protein complex subunit 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EMC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2010 EMD
EDMD
LEMD5
STA
emerin [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EMD mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10436 EMG1
C2F
Grcc2f
NEP1
EMG1 N1-specific pseudouridine methyltransferase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EMG1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27436 EML4
C2orf2
ELP120
EMAP-4
EMAPL4
ROPP120
echinoderm microtubule associated protein like 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EML4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10495 ENOX2
APK1
COVA1
tNOX
ecto-NOX disulfide-thiol exchanger 2 ENOX2 results in increased susceptibility to epigallocatechin gallate increases response to substance
15706060
C045651 10495 ENOX2
APK1
COVA1
tNOX
ecto-NOX disulfide-thiol exchanger 2 epigallocatechin gallate results in decreased activity of ENOX2 protein decreases activity
protein 20518072
C045651 10495 ENOX2
APK1
COVA1
tNOX
ecto-NOX disulfide-thiol exchanger 2 [epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD decreases activity
/ increases abundance
protein 20518072
C045651 114915 EPB41L4A-AS1
C5orf26
NCRNA00219
TIGA1
EPB41L4A antisense RNA 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EPB41L4A-AS1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54566 EPB41L4B
CG1
EHM2
erythrocyte membrane protein band 4.1 like 4B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPB41L4B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57724 EPG5
HEEW1
KIAA1632
VICIS
hEPG5
ectopic P-granules autophagy protein 5 homolog (C. elegans) epigallocatechin gallate results in increased expression of EPG5 mRNA increases expression
mRNA 22079256
C045651 57724 EPG5
HEEW1
KIAA1632
VICIS
hEPG5
ectopic P-granules autophagy protein 5 homolog (C. elegans) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPG5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2043 EPHA4
HEK8
SEK
TYRO1
EPH receptor A4 (EC:2.7.10.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPHA4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9852 EPM2AIP1
EPM2A (laforin) interacting protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EPM2AIP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 22905 EPN2
EHB21
epsin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPN2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2059 EPS8
epidermal growth factor receptor pathway substrate 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPS8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 94240 EPSTI1
BRESI1
epithelial stromal interaction 1 (breast) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPSTI1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23085 ERC1
Cast2
ELKS
RAB6IP2
ELKS/RAB6-interacting/CAST family member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2072 ERCC4
ERCC11
FANCQ
RAD1
XPF
excision repair cross-complementing rodent repair deficiency, complementation group 4 epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in decreased expression of ERCC4 mRNA] decreases expression
/ decreases reaction
mRNA 22079256
C045651 2072 ERCC4
ERCC11
FANCQ
RAD1
XPF
excision repair cross-complementing rodent repair deficiency, complementation group 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERCC4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 375748 ERCC6L2
C9orf102
RAD26L
SR278
excision repair cross-complementing rodent repair deficiency, complementation group 6-like 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERCC6L2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51290 ERGIC2
Erv41
PTX1
cd002
ERGIC and golgi 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERGIC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 157697 ERICH1
glutamate-rich 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERICH1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27248 ERLEC1
C2orf30
CIM
CL24936
CL25084
XTP3-B
XTP3TPB
endoplasmic reticulum lectin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERLEC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55780 ERMARD
C6orf70
dJ266L20.3
ER membrane-associated RNA degradation [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERMARD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10961 ERP29
C12orf8
ERp28
ERp31
PDI-DB
PDIA9
endoplasmic reticulum protein 29 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ERP29 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54206 ERRFI1
GENE-33
MIG-6
MIG6
RALT
ERBB receptor feedback inhibitor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ERRFI1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2098 ESD
FGH
esterase D (EC:3.1.2.12 3.1.1.56) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ESD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 284729 ESPNP
RP1-163M9.1
dJ1182A14.1
espin pseudogene [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ESPNP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2100 ESR2
ER-BETA
ESR-BETA
ESRB
ESTRB
Erb
NR3A2
estrogen receptor 2 (ER beta) epigallocatechin gallate results in decreased expression of ESR2 mRNA decreases expression
mRNA 20706672
C045651 54465 ETAA1
ETAA16
Ewing tumor-associated antigen 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ETAA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2117 ETV3
METS
PE-1
PE1
bA110J1.4
ets variant 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ETV3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2119 ETV5
ERM
ets variant 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ETV5 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2120 ETV6
TEL
TEL/ABL
ets variant 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ETV6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55763 EXOC1
BM-102
SEC3
SEC3L1
SEC3P
exocyst complex component 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXOC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55770 EXOC2
SEC5
SEC5L1
Sec5p
exocyst complex component 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXOC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 60412 EXOC4
SEC8
SEC8L1
Sec8p
exocyst complex component 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXOC4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54536 EXOC6
EXOC6A
SEC15
SEC15L
SEC15L1
SEC15L3
Sec15p
exocyst complex component 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXOC6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23086 EXPH5
SLAC2-B
SLAC2B
exophilin 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXPH5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2139 EYA2
EAB1
eyes absent homolog 2 (Drosophila) (EC:3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EYA2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [F2 protein results in increased activity of F3 protein] decreases reaction
/ increases activity
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [F2 protein results in increased expression of F3 mRNA] decreases reaction
/ increases expression
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [F2 protein results in increased expression of F3 protein] decreases reaction
/ increases expression
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 19944065
C045651 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [F2 protein results in increased activity of F3 protein] decreases reaction
/ increases activity
protein 19944065
C045651 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [F2 protein results in increased expression of F3 mRNA] decreases reaction
/ increases expression
mRNA 19944065
C045651 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [F2 protein results in increased expression of F3 protein] decreases reaction
/ increases expression
protein 19944065
C045651 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 19944065
C045651 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 19944065
C045651 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 19944065
C045651 8772 FADD
MORT1
Fas (TNFRSF6)-associated via death domain [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FADD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3995 FADS3
CYB5RP
LLCDL3
fatty acid desaturase 3 (EC:1.14.19.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FADS3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55179 FAIM
FAIM1
Fas apoptotic inhibitory molecule [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAIM mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 144347 FAM101A
family with sequence similarity 101, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM101A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 284611 FAM102B
SYM-3B
family with sequence similarity 102, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM102B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90362 FAM110B
C8orf72
family with sequence similarity 110, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM110B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 92689 FAM114A1
Noxp20
family with sequence similarity 114, member A1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM114A1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 285966 FAM115C
FAM139A
family with sequence similarity 115, member C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FAM115C mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 79607 FAM118B
family with sequence similarity 118, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM118B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26355 FAM162A
C3orf28
E2IG5
HGTD-P
family with sequence similarity 162, member A epigallocatechin gallate results in decreased expression of FAM162A mRNA decreases expression
mRNA 22079256
C045651 26355 FAM162A
C3orf28
E2IG5
HGTD-P
family with sequence similarity 162, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FAM162A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 400823 FAM177B
family with sequence similarity 177, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FAM177B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51313 FAM198B
AD036
C4orf18
family with sequence similarity 198, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM198B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85395 FAM207A
C21orf70
family with sequence similarity 207, member A epigallocatechin gallate results in decreased expression of FAM207A mRNA decreases expression
mRNA 22079256
C045651 85395 FAM207A
C21orf70
family with sequence similarity 207, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM207A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23272 FAM208A
C3orf63
RAP140
se89-1
family with sequence similarity 208, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM208A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54537 FAM35A
FAM35A1
bA163M19.1
family with sequence similarity 35, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM35A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10447 FAM3C
ILEI
family with sequence similarity 3, member C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM3C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51571 FAM49B
L1
family with sequence similarity 49, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM49B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26240 FAM50B
D6S2654E
X5L
family with sequence similarity 50, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM50B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 199870 FAM76A
family with sequence similarity 76, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM76A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22909 FAN1
KIAA1018
KMIN
MTMR15
FANCD2/FANCI-associated nuclease 1 (EC:3.1.4.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAN1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2176 FANCC
FA3
FAC
FACC
Fanconi anemia, complementation group C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FANCC mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57697 FANCM
FAAP250
KIAA1596
Fanconi anemia, complementation group M (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FANCM mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55711 FAR2
MLSTD1
SDR10E2
fatty acyl CoA reductase 2 (EC:1.2.1.n2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAR2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10667 FARS2
COXPD14
FARS1
HSPC320
PheRS
dJ520B18.2
phenylalanyl-tRNA synthetase 2, mitochondrial (EC:6.1.1.20) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FARS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2194 FASN
FAS
OA-519
SDR27X1
fatty acid synthase (EC:2.3.1.85 2.3.1.38 2.3.1.39 2.3.1.41 3.1.2.14 4.2.1.59 1.1.1.100 1.3.1.39) epigallocatechin gallate results in decreased expression of FASN mRNA decreases expression
mRNA 20816778
C045651 79675 FASTKD1
FAST kinase domains 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FASTKD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22868 FASTKD2
KIAA0971
FAST kinase domains 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FASTKD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2195 FAT1
CDHF7
CDHR8
FAT
ME5
hFat1
FAT atypical cadherin 1 epigallocatechin gallate results in increased expression of FAT1 mRNA increases expression
mRNA 22079256
C045651 2195 FAT1
CDHF7
CDHR8
FAT
ME5
hFat1
FAT atypical cadherin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79633 FAT4
CDHF14
CDHR11
FAT-J
FATJ
NBLA00548
FAT atypical cadherin 4 epigallocatechin gallate results in increased expression of FAT4 mRNA increases expression
mRNA 22079256
C045651 79633 FAT4
CDHF14
CDHR11
FAT-J
FATJ
NBLA00548
FAT atypical cadherin 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAT4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2200 FBN1
ACMICD
ECTOL1
FBN
GPHYSD2
MASS
MFS1
OCTD
SGS
SSKS
WMS
WMS2
fibrillin 1 epigallocatechin gallate results in decreased expression of FBN1 mRNA decreases expression
mRNA 20706672
C045651 2200 FBN1
ACMICD
ECTOL1
FBN
GPHYSD2
MASS
MFS1
OCTD
SGS
SSKS
WMS
WMS2
fibrillin 1 epigallocatechin gallate results in increased expression of FBN1 mRNA increases expression
mRNA 22079256
C045651 2200 FBN1
ACMICD
ECTOL1
FBN
GPHYSD2
MASS
MFS1
OCTD
SGS
SSKS
WMS
WMS2
fibrillin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBN1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2201 FBN2
CCA
DA9
fibrillin 2 epigallocatechin gallate results in decreased expression of FBN2 mRNA decreases expression
mRNA 20706672
C045651 54850 FBXL12
Fbl12
F-box and leucine-rich repeat protein 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FBXL12 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 25827 FBXL2
FBL2
FBL3
F-box and leucine-rich repeat protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26235 FBXL4
FBL4
FBL5
MTDPS13
F-box and leucine-rich repeat protein 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXL4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26234 FBXL5
FBL4
FBL5
FLR1
F-box and leucine-rich repeat protein 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXL5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23194 FBXL7
FBL6
FBL7
F-box and leucine-rich repeat protein 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXL7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84893 FBXO18
FBH1
Fbx18
F-box protein, helicase, 18 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXO18 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 554251 FBXO48
F-box protein 48 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXO48 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 115548 FCHO2
FCH domain only 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FCHO2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9873 FCHSD2
NWK
SH3MD3
FCH and double SH3 domains 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FCHSD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55527 FEM1A
EPRAP
fem-1 homolog a (C. elegans) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FEM1A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 56929 FEM1C
EUROIMAGE686608
EUROIMAGE783647
FEM1A
fem-1 homolog c (C. elegans) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FEM1C mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2241 FER
FerT
PPP1R74
TYK3
fer (fps/fes related) tyrosine kinase (EC:2.7.10.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FER mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10979 FERMT2
KIND2
MIG2
PLEKHC1
UNC112
UNC112B
mig-2
fermitin family member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FERMT2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55785 FGD6
ZFYVE24
FYVE, RhoGEF and PH domain containing 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FGD6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2246 FGF1
AFGF
ECGF
ECGF-beta
ECGFA
ECGFB
FGF-1
FGF-alpha
FGFA
GLIO703
HBGF-1
HBGF1
fibroblast growth factor 1 (acidic) epigallocatechin gallate results in decreased expression of FGF1 mRNA decreases expression
mRNA 20706672
C045651 2257 FGF12
FGF12B
FHF1
fibroblast growth factor 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FGF12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8817 FGF18
FGF-18
ZFGF5
fibroblast growth factor 18 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FGF18 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2247 FGF2
BFGF
FGF-2
FGFB
HBGF-2
fibroblast growth factor 2 (basic) epigallocatechin gallate results in decreased expression of FGF2 mRNA decreases expression
mRNA 16084531
C045651 2247 FGF2
BFGF
FGF-2
FGFB
HBGF-2
fibroblast growth factor 2 (basic) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FGF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11259 FILIP1L
DOC-1
DOC1
GIP130
GIP90
filamin A interacting protein 1-like epigallocatechin gallate results in decreased expression of FILIP1L mRNA decreases expression
mRNA 16084531
C045651 60681 FKBP10
FKBP65
OI11
OI6
PPIASE
hFKBP65
FK506 binding protein 10, 65 kDa (EC:5.2.1.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FKBP10 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 11328 FKBP9
FKBP60
FKBP63
PPIase
FK506 binding protein 9, 63 kDa (EC:5.2.1.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FKBP9 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23768 FLRT2
fibronectin leucine rich transmembrane protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FLRT2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 114793 FMNL2
FHOD2
formin-like 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FMNL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54874 FNBP1L
C1orf39
TOCA1
formin binding protein 1-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FNBP1L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22862 FNDC3A
FNDC3
HUGO
bA203I16.1
bA203I16.5
fibronectin type III domain containing 3A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FNDC3A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64778 FNDC3B
FAD104
PRO4979
YVTM2421
fibronectin type III domain containing 3B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FNDC3B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 163479 FNDC7
RP11-293A10.2
fibronectin type III domain containing 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FNDC7 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54914 FOCAD
KIAA1797
focadhesin [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FOCAD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog epigallocatechin gallate results in decreased activity of FOS protein decreases activity
protein 12663506
C045651 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FOS mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2354 FOSB
AP-1
G0S3
GOS3
GOSB
FBJ murine osteosarcoma viral oncogene homolog B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FOSB mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 27086 FOXP1
12CC4
QRF1
hFKH1B
forkhead box P1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FOXP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 122786 FRMD6
C14orf31
EX1
Willin
c14_5320
FERM domain containing 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FRMD6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10818 FRS2
FRS2A
FRS2alpha
SNT
SNT-1
SNT1
fibroblast growth factor receptor substrate 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FRS2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10129 FRY
13CDNA73
214K23.2
C13orf14
CG003
bA207N4.2
bA37E23.1
furry homolog (Drosophila) epigallocatechin gallate results in increased expression of FRY mRNA increases expression
mRNA 22079256
C045651 10129 FRY
13CDNA73
214K23.2
C13orf14
CG003
bA207N4.2
bA37E23.1
furry homolog (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FRY mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 285527 FRYL
KIAA0826
FRY-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FRYL mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2519 FUCA2
dJ20N2.5
fucosidase, alpha-L- 2, plasma (EC:3.2.1.51) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FUCA2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2530 FUT8
fucosyltransferase 8 (alpha (1,6) fucosyltransferase) (EC:2.4.1.68) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FUT8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2395 FXN
CyaY
FA
FARR
FRDA
X25
frataxin (EC:1.16.3.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FXN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 53827 FXYD5
DYSAD
IWU1
KCT1
OIT2
PRO6241
RIC
FXYD domain containing ion transport regulator 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FXYD5 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2534 FYN
SLK
SYN
p59-FYN
FYN oncogene related to SRC, FGR, YES (EC:2.7.10.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FYN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8321 FZD1
frizzled family receptor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FZD1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2535 FZD2
Fz2
fz-2
fzE2
hFz2
frizzled family receptor 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FZD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55632 G2E3
KIAA1333
PHF7B
G2/M-phase specific E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of G2E3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2548 GAA
LYAG
glucosidase, alpha; acid (EC:3.2.1.20) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GAA mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2549 GAB1
GRB2-associated binding protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GAB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9846 GAB2
GRB2-associated binding protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GAB2 mRNA affects cotreatment
/ decreases expression
mRNA